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Summary	
The discovery of DNA circulating into bloodstream gave rise to several efforts aiming to discover 
its physiological and pathological roles, its clinical utility and its possible use as a powerful 
biomarker that can revolutionise clinical procedures and therapeutic approaches. 
The possibility to obtain information on the behaviour of cancer, graft, infection status or fetus 
conditions through the so-called ‘liquid biopsy’, i.e. the analysis of cfDNA in blood or body fluids, 
with little-to-no invasiveness and having a live, ‘total body’ image representing the entire 
heterogeneity of the system seems promising. 
The application of high throughput analytical procedures, such as Next Generation Sequencing 
(NGS) or digital droplet PCR (ddPCR), are necessary to obtain reliable data on such a small amount 
of starting material. 
Actually only few applications have achieved a clinical validation, due to the great variability in 
pre-analytical procedures that can deeply affect the overall result of the analysis, but cfDNA 
analysis revealed to be useful in particular in those clinical settings in which it is difficult to obtain 
other tissues, such as lung cancer, or repetitive biopsies can affect dramatically the outcome of the 
patient, as in transplantation. 
 
In our work we applied cfDNA analysis to three different clinical settings. 
 
In the first, we evaluated the presence of mutation in a panel of 16 genes belonging to the 
Homologous Recombination (HR) pathway in cfDNA and genomic DNA extracted from nodules in 
patients affected by breast cancer. 
This analysis revealed the presence of mutations in 3 out of 6 samples. Interestingly, in one case we 
observed a higher variant fraction in cfDNA compared to genomic DNA, probably due to limited 
ability to detect clonal heterogeneity in tissue. 
 
In the second clinical setting we evaluated if cfDNA can be used as a monitoring tool for 
determining septic risk. We analysed samples taken from patients undergoing dialysis with clinical 
symptoms suggesting the need of an emoculture test for bacterial systemic infection. 
We were able to detect with high confidence the presence of bacterial strains in two samples. 
Interestingly, in the first one we detected, in accordance with the emoculture, a Staphylococcus 
strain together with Propionibacterium and Streptococcus strains. 
The detection of Burkholderia multivorans in the second sample rised the possibility to identify 
with our technique those bacteria that take more than the canonical 5 days of emoculture to growth, 
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or that completely do not grow in emoculture conditions, sustaining the hypothesis of a, even if by 
now far in the future, culture-independent microbiology. 
 
The third set of samples analysed was obtained from patients undergoing kidney transplantation. 
We wanted to verify the applicability of the AmpFlSTR® Identifiler® Plus PCR Amplification kit 
to cfDNA in order to monitor graft status. 
We started analysing 3 patients having kidney biopsy due to clinical symptoms of graft rejection. 
We were not able to detect any donor-derived polymorphism in these samples. 
We thus decided to analyse samples in which we were sure to have donor-derived cfDNA (dd-
cfDNA). We collect blood samples from patients undergoing transplantation just after reperfusion 
of the graft and 1, 4 and 8 days after surgery. 
We were able to identify more than 50% of donor derived polymorphisms just after reperfusion, 
thus falling down to 10% one day after surgery and disappearing from day 4 on. 
This data are in accordance with the literature, describing a huge amount of dd-cfDNA just after 
transplantation released by reperfusion injury. 
 
Data by now obtained seems promising, even if preliminary. 
The possibility to cross our data with clinical parameters will help us to better describe the 
pertinence of our results to the effective status of patients. 
In all the three settings, we are collecting other samples to have a broader amount of data that will 
allow us to perform statistical analysis to effectively validate our procedures. 
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INTRODUCTION	
 
1	Circulating	cell-free	DNA	(cfDNA)	
 
The first description of the presence of DNA freely circulating into the bloodstream dates back to 
1948, when Mandel and Métais identified extracellular nucleic acids in blood of both healthy and 
diseased people (Mandel and Métais, 1948). 
 
1.1	History	
 
During the 60s several studies conduced in patients affected by Lupus Erythematosus (LE) 
discovered important features of DNA in blood.  
Ceppellini and colleagues, starting from the hypothesis that DNA can elicit specific antibodies 
(Ab), identified a DNA-reacting factor in serum obtained from a patient affected by LE Diffusus. 
They then purified DNA from different samples of both human and animal origin and verified if 
they observed a reaction after incubation with LE serum. The choice of a LED affected patient was 
due to two main reasons: a) nuclear material released by nucleolysis, that is typical of this disease, 
can get in contact with immunological components; b) subjects affected by LE produce a huge 
amount of auto- and iso-Ab, thus increasing the probability to have anti-DNA Abs (Ceppellini et 
al., 1957). They effectively observed a factor able to interact with DNA from different sources and 
species that behave like an antibody, but the fact that other sera obtained from eight other patients 
did not showed reactivity drive the explanation of the phenomenon toward a patient-specific 
autoimmune hyperreactivity (Ceppellini et al., 1957). 
Following experiments demonstrated not only an association between the presence of anti-DNA 
Abs in the serum and the acute phase of SLE, but also that these Abs are able to interact with either 
autologous and eterologous DNA, suggesting an active role of the DNA-anti-DNA complex in 
disease progression, in particular in driving renal disease and vasculitis (Casals et al, 1964). 
Two years after, Tan and colleagues demonstrated the possibility to use sera obtained from SLE 
patient to detect the presence of DNA in blood. Starting from calf thymus DNA, they performed 
experiments on DNA-anti-DNA recognition in three different conditions: native DNA (i.e. 
dsDNA), sonicated DNA (i.e. small dsDNA fragments) and heat denatured DNA (i.e. ssDNA). 
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They observed an identical behaviour of the native and sonicated DNA, suggesting identical 
antigenic properties. Interestingly, they observed that serum that had reacted with dsDNAs was able 
to react also with ssDNA, suggesting the presence of Abs specifically and independently 
recognising the two forms (Tan EM, Schur PH et al, 1966). The complete abolishment of the 
reaction after DNase treatment pointed definitely toward DNA as the antigen in sera (Tan EM, 
Schur PH et al, 1966). 
Even if the presence of DNA in plasma of patients affected by cancer was demonstrated by Tan and 
colleagues in 1966, it took around a decade to specifically study how circulating DNA behave in 
cancer-affected patients. Radioimmunoassays were developed to quantify the presence of ng 
amounts of DNA: [I
125
]iododeoxyuridine-labeled DNA worked as an antigen and LE patient’s 
serum as source of Abs. Leon and colleagues were able to evaluate the amount of cfDNA in serum 
of 173 cancer patients and 55 healthy people with this assay, identifying a median concentration of 
DNA of 13 ± 3 ng/ml plasma and 180 ± 38 ng/ml plasma in healthy and cancer patients, 
respectively. They also detected higher amount of DNA in patients with metastatic cancer respect to 
nonmetastatic ones (Leon et al, 1977). 
The application of the assay after radiation therapy of patients revealed a decreased amount of 
cfDNA in those patients in which clinical conditions improved, i.e. decrease of tumour size or 
reduction of pain, whereas a lack of response to the therapy was associated to increase or no 
changes in DNA levels (Leon et al, 1977). 
50% of patients enrolled in this study showed circulating DNA levels comparable to healthy 
subjects, but this situation can be explained by the fact that the only inclusion criteria of this 
research was to be selected for radiation therapy without taking into account previous surgery or 
chemotherapy that could have affected the amount of free DNA (Leon et al, 1977). 
These data taken together suggested the hypothesis that also tumours are capable of releasing 
circulating DNA, as previously observed by this group in cultured human normal lymphocytes 
(Anker et al, 1977) and confirmed by the analysis of DNA released in the medium by leukemic 
cells obtained from a patient, even if conditions that drive this phenomenon were not known. 
Researchers finally hypothesized that cancerous DNA can play a transfectant role and contribute to 
the diffusion of the tumour (Stroun et al, 1989). 
The possibility to study cfDNA at the molecular level increased information on this field. 
Vasioukhin and colleagues identified K-ras mutation in circulating, tumour and blood-isolated cell 
DNA of patients affected by colorectal adenocarcinoma (Vasioukhin et al, 1992; Vasioukhin et al, 
1993) and N-ras mutation in DNA obtained from plasma, circulating cells and bone marrow of 
patients with myeloid leukemia or myelodisplastic syndrome (Vasioukhin et al, 1994). They 
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observed that N-ras mutations identified in plasma DNA were not always detected analysing the 
other sources of DNA, suggesting strong medical implication: no identification of mutations into 
bone marrow DNA can be explained by the fact that needle biopsy collect just a small fraction of 
bone marrow, thus it is likely that not all the malignant clones are included into the analysis, while 
the absence of the mutation in blood cells can be linked to the apparent remission state of patients 
or to the fact that cancer cells can remain into bone marrow. 
This last observation can be considered a precursor of the ‘liquid biopsy’ concept: the possibility to 
identify a mutation in plasma DNA, reducing the probability to miss the malignant clone, can 
furnish fundamental clinical information, considering that presence of ras mutations in myeloid 
disorders is a poor prognostic factor at diagnosis (Padua et al, 1988) and reflects efficacy of 
chemotherapy in achieving clinical remission (Senn et al, 1988). 
The detection of fetal DNA in both plasma and serum of pregnant women further expanded the 
field of liquid biopsies. Lo and colleagues, amplifying Y sequences in male-fetus-bearing women 
(Lo et al, 1997), paved the way toward non-invasive prenatal diagnosis of fetal trisomies and 
genetic anomalies, such as Down syndrome (Yu et al, 2014), but also important biological 
characteristics such as sex (Mennuti et al, 2015) and Rhesus factor or blood group (Rieneck et al, 
2015). Even more interestingly, the possibility to analyse extracellular DNA released by embryonic 
cells in culture can prevent the aspiration of one or two cells from embryos after in vitro 
fertilization (IVF) with the conceivable complications and risks associated to the procedure, thus 
maintaining the levels of information obtained by sequence and structure analysis (Assou et al, 
2014; Thierry et al, 2016). 
 
1.2	Biological	features	of	cfDNA	
 
1.2.1	Fragment	size	
	
We have already described the work done by Tan and colleagues in 1966, that demonstrated the 
presence of DNA-anti-DNA complexes in blood of SLE patients. 
The isolation of the DNA-anti-DNA complex allowed a better characterization of circulating DNA. 
It was demonstrated that DNA in these complexes is double stranded and fragments were of 30-40 
bp in length (Sano and Morimoto, 1981). 
Stroun and Anker in 1987 analysed circulating DNA from patients with different malignancies, 
proving the existence and characterizing tumour-released cfDNA. They firstly confirmed that DNA 
in cancer patient is mainly double stranded and observed a heterogeneous fragment composition, 
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with size of the fragments ranging between 21 kb to less than 500 bp, thus smaller than genomic 
DNA (Stroun et al, 1987). 
The application of an in vitro DNA synthesis test, consisting in a DNA synthesis reaction 
performed in presence of carcinogens, allowed to determine if DNA was originated from cancer, if 
the reaction takes place, or normal cells, i.e. no synthesis, resulting in the presence of cancer-
derived circulating DNA in 5 out of 7 samples analysed, while the other 2 presented only non-
tumoral DNA. The increase in absorbance in those 5 samples, as the result of the hyperchromicity 
test, suggested double strand instability of the newly synthesized DNA, a typical characteristic of 
tumoral DNA (Stroun et al, 1989). 
Fragmentation profiles revealed the coexistence of at least three sets of fragments, characterized by 
different length: 
- 180-200 bp fragments and their multiples 
- more than 10000 bp fragments 
- fragments smaller than 150 bp 
 
 
1.2.2	cfDNA	bioavailability	
	
A critical step in cfDNA comprehension concern mechanisms by which it is released and circulates 
into the bloodstream and how it interacts with other cells (Fig. 1). 
 
 
 
Fig. 1: potential vesicles that transport cfDNA. From Thierry et al. (2016). 
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1.2.3	Apoptotic	bodies	
	
Apoptotic bodies have been addressed as a source of cfDNA, even if nowadays there are still open 
questions on this hypothesis. These vesicles measure 1-5 µm, are produced in the late stage of 
apoptosis by membrane blebbing and contain part of the cytoplasm and DNA degraded by caspase-
activated DNase during apoptosis (Stroun et al, 2006; Vlassov et al, 2007). 
Surely the characteristic ladder pattern observed in cfDNA (Jahr et al, 2001) indicates apoptosis as 
a source of cfDNA and, as a result, apoptotic bodies as the way in which it is released. Several 
studies associated the amount of cfDNA to apoptosis of neoplastic cells due to fragment 
composition and comparison with other markers of apoptosis (Giacona et al, 1998). 
On the other hand, apoptotic bodies should be cleared in situ by epithelial cells and macrophages, 
thus contribution to circulating DNA should be limited (Stroun et al, 2006). 
 
1.2.4	Microvesicles	
	
Microvesicles are membrane-surrounded particles containing an aqueous compartment. 
The observation of abnormal production of microvesicles in cancer patients (Mouliere et al, 2012; 
D’Souza-Schorey and Clancy, 2012), in addition to their role in genetic information transfer and 
cell-to-cell communication (Lee et al, 2012; Turturici et al, 2014), strictly connect these structures 
to cfDNA. 
Depending on the process generating them, microvesicles are divided into: 
• exosomes: 30-100 nm in diameter, these structures are secreted by most cells and can 
transfer material laterally, i.e. horizontally between different cells (De Jong et al, 2014). 
They contain proteins, particular lipids, messenger RNA (mRNA), micro RNA (miRNA) 
and variable amount of DNA (Thakur et al, 2014). Interestingly, it has been demonstrated 
that this DNA component is characterized by two sets of fragments: a membrane-bound, 
large size dsDNA and a small fragment DNA inside the exosome (Thakur et al, 2014). More 
recently, Rohan-Fernando and colleagues observed that a large proportion of plasma cfDNA 
is localized into exosomes (Rohan-Fernando et al, 2017). 
• Microparticles: membrane fragments of 200 - 1000 nm in diameter, released by eukaryotic 
cells and they contain both DNA and RNA. 
• Apoptotic bodies 
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1.2.5	Macromolecular	complexes	and	the	Virtosome	
	
The possibility that DNA circulates in macromolecular complexes was confirmed in several SLE 
studies, describing the association between DNA and Abs.  
A DNA/RNA-lipoprotein complex was described for the first time in 2010 by the Stroun group. 
This macromolecular complex is actively released by cells in a regulated fashion (Gahan and 
Stroun, 2010). This discovery confirmed studies on active release of DNA in the medium of 
cultured lymphocytes (Rogers et al, 1972; Anker et al, 1975), frog heart auricles (Stroun and Anker, 
1972), rat spleen (Adams and Gahan, 1983) or leukemia cell line HL-60 (Abolhassani et al, 1994) 
and the hypothesis of an active DNA release mechanism (Stroun et al, 2001). 
Studies on this complex revealed that all the components are newly synthesized only by living cells 
(Anker et al, 1975; Stroun et al, 1978; Adams and Gahan, 1983), that the complex is released in a 
energy-dependent process (Adams and Gahan, 1983) and in a controlled manner (Anker et al, 1975; 
Stroun et al, 1977). Analysis in chick embryo fibroblasts demonstrated that this complex could be 
uptaken by cells (Adams and McIntosh, 1985). 
1.2.6	Extracellular	DNA	Traps	
	
It is well known that both neutrophils and eosinophil are involved in tumour-associated 
inflammatory infiltrate, where they can acts as both pro- and anti-tumorigenic depending on their 
activation status, and both are able to generate extracellular DNA traps, i.e. DNA associated with 
other cellular structures. 
In particular, NETosis is a cell death program following neutrophil activation consisting in 
chromatin decondensation, lysis of membranes and neutrophil extracellular DNA traps (NETs) 
release (Brinkman et al, 2004). This complex of DNA fibers and anti-microbial granules is involved 
in trapping and killing pathogens (Papayannopulos et al, 2010). A so-called “vital NETosis”, a 
process in which NETs are released without cell lysis, has also been described (Yipp and Kubes, 
2013). 
Differently from NETs, eosinophil extracellular DNA traps (EETs) are actively secreted by a 
catapult-like manner after eosinophil activation and they are composed of only mitochondrial DNA 
(Youssefi et al, 2008). An important feature of EETs is that eosinophils remain viable during this 
process and no “EETosis” is evidenced (Youssefi et al, 2008; Youssefi et al, 2012). 
So far, NET release has been described in several pathological conditions, such as infections, 
autoimmune pathologies, thrombotic illnesses and inflammatory response (Kaplan and Radic, 2012; 
Cooper et al, 2013), metastases promotion and progression (Cools-Lartigue et al, 2013; Tohme et 
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al, 2016) or after exercise (Beiter et al, 2014), all conditions characterized by high cfDNA levels, 
suggesting a contribution of this structure to circulating DNA population. 
 
1.2.7	Serum	Proteins	
	
Since the 60s it is well known that both single and double strand DNA can interact with Ab, 
forming the so-called DNA-anti-DNA complex, that is involved in SLE progression (Casals et al, 
1964; Tan et al, 1966; Rykova et al, 1994). 
Due to its electrostatic nature, DNA can link with proteins such as albumin, fibronectin and the C1q 
complement component (Rykova et al, 2012). 
Thus, pathological conditions altering serum protein availability can affect the amount of cfDNA in 
blood (Thierry et al, 2016). 
 
1.2.8	Cell	Surface-Bound	cfDNA	
	
Both DNA and RNA can be found on leukocytes and erythrocytes membranes (Rykova et al, 2012; 
Laktionov et al, 2004). In vitro studies revealed 20 kbp DNA fragments on cell surfaces (Morozkin 
et al, 2004), either naked or associated with macromolecules. 
 
 
1.3	Signature	of	the	release	mechanism	
	
Information on processes generating cfDNA fragments can be deduced by fragment themselves. 
The analysis of cfDNA in cancer patients by PAGE, performed by Jahr and colleagues, revealed 
two main sets of fragments well distinguishable on the base of their size, despite a strong variation 
between samples. They observed a mono- and oligonucleosomal DNA ladder, i.e. DNA of ∼180 bp 
and multiple thereof in lengths, and a high molecular weight fraction of ∼ 10000 bp. 
Model studies on both cell lines and animals confirmed apoptosis and necrosis as two mechanisms 
generating the oligonucleosomal ladder and the high molecular weight fraction, respectively (Jahr et 
al, 2001). 
A third set of fragments, that is probably the most clinically relevant among cfDNA, was 
discovered nearly a decade after these findings. 
Mouliere and colleagues, in fact, observed a great variation in cfDNA quantification on the base of 
the length of the amplicon amplified by PCR. In particular, they determined that nearly 80% of 
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tumoral derived cfDNA was missed when 150-300 bp amplicons were used for the analysis and 
suggested amplicons of <100 bp as the best (Fig. 2). 
High proliferation and apoptosis rates observed in tumours can explain the reduced integrity 
observed, i.e. minor length of the fragments, and further supports apoptosis as an important source 
of tumoral circulating DNA (Mouliere et al, 2011; Madhavan et al, 2014). 
  
 
Fig 2: cfDNA fragment size distribution of mutant and wild type cfDNA. A) plasma of CRC affected patients B) 
xenografted animal model. From Mouliere et al, 2011. 
 
The identification of tumour causative mutations (Vasioukhin et al, 1992-1993-1994; Sorenson 
1994) or the lower length of fragments (Mouliere et al, 2011; Madhavan et al, 2014) clearly 
indicates that tumours produce and release DNA fragments into the bloodstream. 
The identification of cfDNA in healthy people raised the question on which tissues contribute to 
this population. Lack of a genetic biomarker as mutations that clearly indicates the origin of the 
fragment had been a limitation in this field and in those pathological conditions associated with an 
increased cfDNA, such as myocardial infarction (Chang et al, 2003), stroke (Rainer et al, 2003) or 
autoimmune disorders (Galeazzi et al, 2003), that do not present a genetic discriminant between 
healthy and pathologic cellular status. Nucleosomal occupancy can be a powerful marker of tissue 
contribution in the absence of a mutation, as described by Snyder and colleagues. 
Starting from the established association between cfDNA fragments and nucleosomal DNA, they 
hypothesized that cfDNA sequences must reflect at least in part the epigenetic landscape of the cell, 
and thus tissue, of origin. By deep sequencing of cfDNA fragments and maps of nucleosomal 
occupancy, they were able to indicate lymphoid and myeloid cell lines as the source of 
physiological cfDNA, confirming previous works (Lui et al, 2002), and revealing the contribution 
of different tissues in samples of different cancer patients (Snyder et al, 2016). 
An alternative “genotype-independent” method to analyse cfDNA is represented by methylation. 
Epigenomic profiling and cancer-specific DNA methylation patterns can furnish clinical issues in 
	 13
diagnosis, prognosis and disease monitoring and thus can be considered a marker of tumour DNA 
(Warton et al, 2016). 
One advantage of analysis on cancer-associated methylation modification or nucleosomal 
occupancy is that they do not require knowledge of the patient-specific mutational profile or to 
apply libraries of assays covering the most common mutations related to a specific type of tumour. 
The first analysis on cfDNA methylation in different diseases was performed by Lehmann-Werman 
and colleagues. They firstly identified tissue-specific DNA methylation patterns and then looked at 
those markers into cfDNA. They were this way able to identify pancreatic β cells as the source of 
cfDNA in insulin-dependent diabetic samples, oligodendrocytes in patients affected by multiple 
sclerosis, neuronal/glial origin of cfDNA after both cerebrovascular accident or heart attack and 
exocrine pancreatic cell in subjects with pancreatitis or pancreatic cancer (Lehman-Werman et al, 
2016). 
Circulating methylated DNA has also been proved to be a predictive and prognostic marker in 
metastatic colorectal cancer after treatment with Regorafenib. In particular, high baseline 
methylated DNA is associated with worst prognosis and shorter progression free survival during 
treatment (Amatu et al, 2019). 
 
 
1.4	cfDNA	halflife	and	clearance	
	
Starting from the 60s, several works were focused on deciphering free circulating DNA halflife and 
kinetics. Tsumita and Iwanaga firstly detected radioactivity at different times after tritiated calf 
thymus DNA injection into mice bloodstream. They observed two phases of radioactivity decrease: 
the first was quite rapid, 30 mins, and corresponded to >99% reduction in radioactivity; the second 
presented a slow decrease in radioactivity loss. Analysis of organs revealed that kidneys represented 
the main way of excretion, even if a fraction of radioactivity was trapped in liver tissues even 3h 
after injection (Tsumita and Iwanaga, 1963). Chused et al implemented previous data by analysing 
clearance of dsDNA and ssDNA in different mice strains. They observed that ≥50% of injected 
nucleic acids, whether ss or ds, was cleared in 1 min, rising to 90% in 20 mins. Denaturated DNA 
was removed slighty faster than dsDNA and incubation with endogenous nucleases revealed that 
most of the DNA is uptaken as macromolecule or complexed with antibodies, more than digested. 
The analysis of organs suggested a pivotal role of liver and spleen, via reticulo-endothelial uptake, 
in DNA clearance (Chused et al, 1972). 
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Dorsch and colleagues compared clearance rate of ssDNA in rabbits non-immunized and 
immunized with ssDNA, obtained by heat denaturation. 
They injected both rabbits with I
125
-calf thymus ssDNA and they observed that in the presence of 
anti-ssDNA Abs ssDNA clearance was delayed and persistence of DNA-anti-DNA complexes can 
affect pathogenesis of immune complexes disease (Dorsch et al, 1975). 
These observations seemed in contrast with the high levels of circulating DNA observed in SLE 
patients. Emlen and Mannik thus hypothesized that in some conditions either DNA clearance is 
altered, or SLE DNA is somehow different from experimental DNA or larger amounts of DNA are 
released. 
To better understand this phenomenon, they administered several doses of I
125
-ssDNA, ranging 
from 2 µg to 500 µg, and collected blood at different times (30 s - 8h). As expected, ssDNA at 
doses comparable to previous experiments was cleared in an analogous time and the liver was the 
main organ involved, suggesting phagocytosis by Kupffer cells as the main physiological process at 
the base of clearance. Saturation of phagocytosis explains how an amount of ssDNA higher than the 
threshold resulted in DNA accumulation into the bloodstream. The kinetics observed for high dose 
ssDNAs effectively were saturable for both blood clearance and liver uptake processes. Kidneys 
showed an uptake independent on DNA dose administered, in the amount of 2-5% of total removal, 
and spleen started uptaking DNA once liver got saturated but played a minor role in the process.  
The mechanism of DNA clearance seemed to involve circulating nucleases that cleaves large 
molecular weight ssDNA into smaller fragments that are bound by liver, where a membrane 
exonuclease releases nucleotides into the bloodstream. The latter step is the one that gave the 
saturable feature at the system, supporting the fact that SLE patients show high levels of circulating 
DNA (Emlen and Mannik, 1978). 
Pancer and colleagues observed that splenic lymphoid cells maintained in culture spontaneously 
released into the media a unique species of DNA of 145-185 bp in length, predominantly double 
stranded and able to induce anti-DNA Ab, against both ssDNA and dsDNA, if injected into mice 
(Pancer et al, 1981). 
In 1984 Emlen and Mannik went deeper in understanding DNA behaviour studying clearance and 
organ uptake of both ssDNA and dsDNA of different sizes in normal mice. They described the two 
steps clearance consists of: organ uptake, that was more rapid for ssDNA than dsDNA, and 
excretion of waste products, that did not showed differences between different preparations. They 
concluded that ssDNA is cleared in around 20 mins mainly by the liver, while dsDNA remains in 
the circulation longer, till 40 mins, and is mainly metabolized by circulating nucleases. This latter 
result was in agreement with lower levels of nucleases characterizing SLE patients, leading to 
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accumulation of circulating dsDNA that forms DNA-anti-DNA complexes (Emlen and Mannik, 
1984). 
A direct analysis on cfDNA, thus not involving externally injected DNA, was performed by Lo and 
colleagues in 1999. They looked at fetal circulating DNA clearance in 8 pregnant women about to 
give birth and observed a two phases process that pointed out a median 16.3 mins half-life for 
cfDNA (Lo et al, 1999). Several years after, a massively parallel sequencing approach indicated a 
1h half-life for the first phase and a 13 h half-life time for the second phase (Yu et al, 2013). 
The analysis of post-surgery cfDNA clearance in a patient affected by CRC revealed a half-life of 
114 mins (Diehl et al, 2008). 
Discrepancies observed in half-life determination can be explained accounting for different clinical 
and experimental settings, i.e. externally injected DNA vs effective cfDNA, model organisms vs 
patients, different pathological conditions, and a still not clear characterization of release rate, but 
determination of fate and turnover of cfDNA is necessary to comprehensively understand the 
biological role of cfDNA and to develop tools for biomedical and clinical applications (Thierry et 
al, 2016). 
	
1.5	cfDNA	functions	
	
Several functions have been attributed to cfDNA, on the base of its structure and way of circulation. 
1.5.1	Intracellular	messenger	
	
We have already described Stroun, Anker and Gahan works that described virtosome (Gahan and 
Stroun, 2010). Studies on intracellular messengers dated back to the 60s and involved the concept 
of non-sexual transmission of characters observed mainly in plant species and graft experiments. 
Experiments on plant grafts revealed that characteristics of the graft were transmitted to the 
progeny, originated by the stock (Stroun, 1962). An analogous situation was observed in feather 
colour modification in white chickens after blood transfusion from Guinea hens (Stroun et al, 
1962). 
The discovery of virtosome and its active and regulated secretion in the medium of cultured cells 
suggested virtosome could play an intracellular messenger role. 
Actually, the virtosome ability to penetrate into cells was demonstrated much earlier than its 
description. Several works described the intercommunication between different types of cells 
already in the 80s. It was already known that lymphocytes in culture release actively and 
spontaneously newly synthesized DNA into the culture medium (Anker et al, 1975). Experiments 
on T and B cells in culture revealed that T cell released DNA after HSV exposure was able, once 
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added to B cell culture medium, to induce anti-HSV antibody synthesis by unexposed B cells. More 
interestingly, those Ab presented peculiar anti-allotypes of T cells (Anker et al, 1980). Analogous 
experiments were performed on mice that were injected with DNA released in the medium by T cell 
after HSV or poliovirus exposure. Parallel to the previous experiment, mice started producing 
human-like anti-polio and anti-HSV Abs (Anker et al, 1984).  
 
1.5.2	Genometastases	
	
Strictly associated to the ability to act as an intracellular messenger is the concept of 
genometastases, i.e. the capacity of tumoral cfDNA to transfect healthy cells far from the primary 
tumour and this way direct the formation of metastases. The possible involvement of cfDNA in 
oncogenesis was hypothesized back in 1965, when it was observed that the injection of tumour 
DNA in mouse bloodstream results in tumour development (Bendich et al, 1965). In 1994, Anker 
and colleagues observed that NIH/3T3 cells grown into medium of cultured SW480 cell, that carry 
a k-ras mutation, acquired the mutation identified in SW480 and became tumorous (Anker et al, 
1994). An analogous situation was observed with the addition of plasma obtained from colorectal 
cancer patient carrying a mutated KRAS (Garcia Olmo et al, 2010). Furthermore, NIH/3T3 cells 
treated this way were able to induce tumour formation once injected into nude mice (Fig. 3) (Garcia 
Olmo et al, 2010). 
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Fig. 3: schematic representation of genometastases proving experiment. Plasma from colon cancer 
patients, containing DNA carryng the mutated K-ras (GAT trinucleotide), added to the medium of 
NIH/3T3 (wild type K-ras) resulted in the acquisition of the mutant K-ras from the cells. Mice 
injected with the transformed cells develop K-ras mutated tumors (from Garcia Olmo et al, 2010). 
 
Mechanisms sustaining this phenomenon can be multiple and involve several cfDNA carriers. All 
the cfDNA-containing vesicles, i.e. apoptotic bodies, microvesicles and exosomes, can be 
responsible for genetic material transfer (Peters and Pretorius, 2012). Nucleosomes are equally able 
to cross plasma membrane, thus penetrating into the cell (Hariton-Gazal et al, 2003). 
Macromolecular complexes involving proteins into the bloodstream also favours DNA 
internalization. The virtosome, finally, has a clear ability to penetrate into cells and alter their 
genetic landscape, as shown by experiments on NIH/3T3 cells described earlier. 
A series of experiments shed light on events that follow cfDNA uptake. Mittra and colleagues 
discovered that cfDNA, once uptaken, is integrated by host cells into their genome (Mittra et al, 
2015) and that this event induces apoptosis and DNA damage responses (Fig. 4) (Mittra, 2015). 
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Fig. 4: induction of γ-H2AX, an indicator of dsDNA breaks, and active Caspase-3, an 
indicator of apoptosis, in NIH/3T3 cells treated with fragmented circulating DNA 
(DNAfs). DNAfs from cancer patients (grey bars) induces a higher response compared to 
those coming from healthy donors (adapted from Mittra et al, 2015). 
 
 
1.5.3	Pro-inflammation	mediator	
 
It is well known that DNA is an immunostimulating molecule, considering its double-helix 
structure and the ability to interact with other molecules and sequence motifs. This data is supported 
by the observation of activation of interferon (INF) and pro-inflammatory molecules secretion in 
cells of the innate immune system after DNA exposure (Pisetsky, 2012). The abundance of nucleic 
acid specific receptors further supports an immunological function of DNA (Kawasaki et al, 2011). 
We have already described the role of circulating DNases in maintaining scarce levels of DNA, thus 
blocking its ability to stimulate cells, and the case of SLE patients, presenting low levels of DNase 
activity, characterized by autoimmunity and accumulation of cfDNA. 
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Several studies indicated that cfDNA acts like a damage-associated motif pattern (DAMP), i.e. 
endogenous ligands that can be recognized by Toll Like Receptors (TLRs) and activate the TLR-
MyD88 (Myeloid differentiation primary response gene 88) pathway, leading to NF- κB and AP1 
production (Fig. 5) (Klinman, 2004). These transcription factors, then, regulate the expression of 
inflammatory cytokines, as tumour necrosis factor or interleukines (IL) 1 and 6, and costimulatory 
molecules such as CD80 and CD86 (Kawai and Akira, 2010). 
 
Fig. 5: schematic representation of the interaction between DNA and TLR9 receptor. DNA 
internalization is facilitated by class III Phosphatidylinositol 3-kinase. Once in the endosome 
DNA binds to TLR9 and TLR-MyD88 pathway is activated. Several downstream factors are 
activated, leading to NF-κB and AP1 activation and gene transcription. CpG ODN: CpG 
OligoDeoxyNucleotides (from Klinman, 2004). 
 
TLR9 is a DNA receptor that recognizes oligonucleotides of 20-30 nt containing demethylated CpG 
motifs (Yasuda et al, 2009). For this reason, it is physiologically involved in sensing microbial 
DNA, either viral or bacterial, and it is usually located into intracellular vesicle membranes in 
dendritic cells and macrophages (Fehri et al, 2016; Nakagawa and Gallo, 2015). The expression of 
TLR9 has been evidenced also in cancer cells and its high levels are associated with poor survival 
in patients affected by several cancers, among which glioma, prostate and esophageal 
adenocarcinoma (Vaisanen et al, 2013; Zhang et al, 2014). Even if a direct correlation between 
cfDNA and TLR9 in cancer has not been determined, the hypomethylated DNA profile in several 
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cancers can be a condition favouring cfDNA and TLR9 interaction and subsequent effects on 
cancer cells (Niu et al, 2018). 
A study on CRC derived cell lines revealed that cfDNA of tumour origin is able to induce 
proliferation, promote cell migration and invasion and stimulate secretion of IL8, which has a 
pivotal role in malignancy, due to interaction with TLR9 (Niu et al, 2018). 
 
 
1.5.4	Tumour	progression	
	
Discovery of NETS and EETS opened a new field of investigation. NETS, in particular, have 
already been associated to cancer progression (Demers and Wagner, 2013). 
Polynuclear cells produce NETS and EETS after stimulation by pathogens and/or particular 
pathophysiological conditions, as inflammation (Wartha et al, 2007). Polynuclear neutrophil levels 
in the bloodstream correlate negatively with overall survival rate, due to their involvement in 
forming “bridges” between circulating tumour cells and epithelia of both lung and liver (McDonald 
et al, 2009). It has also been demonstrated that NETS can sequester circulating tumour cells 
promoting metastasis formation by increasing adhesion to epithelial cells (Cools-Lartigue et al, 
2013). 
 
1.5.6	Therapeutic	target	
	
Considering all these physiological and pathological conditions in which cfDNA is involved, it can 
be reasonably considered a potential target for therapies. In particular, tumour progression via 
genometastases and DAMP-induced activation of the immune system are the main field in which 
therapy can be hypothesized. 
Experiments on cancer cell lines xenografted onto mice were used to verify the efficacy of DNase 
and RNase treatments. Lung tumour-bearing mice treated daily with low doses of DNase and 
RNase presented reduced metastatic progression (Fig. 6) (Patutina et al, 2011). Reduced tumour 
progression was observed also in mice injected with DNA obtained from the medium of SW480 
cell cultures, after DNase treatment (Trejo-Becerril et al, 2012). 
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Fig. 6: effects of RNase A and DNase I treatment on metastasis development in a Lewis lung 
carcinoma (LLC) metastatic mouse model. As we can see, lung lobes in control animals are 
characterized by several large metastasis (arrow). Mice treated with either RNase A (second line) 
or DNase I (third line) showed a great reduction in metastasis number and dimension (from 
Patutina et al, 2011). 
 
NETS destruction can be achieved with either DNase or neuro-elastase inhibitors (Cools-Lartigue et 
al, 2013). 
A third therapeutic option involves cationic polymers that electrostatically interact with cfDNA 
inhibiting the inflammatory response without affecting immune system (Holl et al, 2013).	
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2	Breast	Cancer	
2.1	Epidemiology	
	
Breast cancer is the most common neoplasia in women worldwide. One woman out of eight in the 
United States will develop breast cancer during her life (DeSantis et al, 2013). In Italy, in 2018, 
about 52,800 new cases were diagnosed (AIOM, 2018). 
It is also the leading cause of death, representing the 29% of the causes of oncological death before 
the age of 50, 21% between 50 and 69 years and 14% after 70 years (AIOM, 2018). In Italy the 
relative survival, is 87% at 5 years and 80% at 10 years.  
2.1.1	Risk	Factors	
	
Considering that most breast cancers are sporadic, it is difficult to clearly determine specific, and 
therefore predictable, risk factors.  
Those factors that mostly determine the risk of developing breast cancer are: 
SEX: The vast majority (99-99.5%) of breast cancer affects women. Male breast cancer is rare 
(Ruddy et al, 2013). 
AGE: The risk of developing breast cancer progressively increases with age, reaching a peak 
around 50 years; starting from this age it continues to grow even more slowly. The probability of 
developing breast cancer within the age of 49 is 2.4% (1 out of 42 women), 5.5% between 50 and 
69 (1 out of 18 women) and 4.7% among 70 and 84 years (1 woman out of 21). This trend seems to 
be due to the continuous endocrine-proliferative stimulus that the mammary gland receives, 
combined with the progressive damage to the DNA and to the accumulation of epigenetic 
alterations that modify the expression of oncogenes and tumor suppressor genes. 
FAMILIARITY AND INHERITANCE: Most breast cancers are sporadic. A woman with a family 
of first degree positive for breast cancer has a doubled chance of developing breast cancer (Rhodes 
2002). Only in 7-8% of cases the tumor is defined as hereditary (Rovera et al, 2018). The mainly 
involved genes are BRCA1 and BRCA2 (genes with autosomal dominant transmission), which are 
normally involved in DNA repair processes (Karami and Mehdipour, 2013; Chen and Parmigiani, 
2007). These genes are also associated with ovarian cancer. Other high penetrance genes associated 
with breast cancer are TP53, PTEN CHD1, STK1113. Then there are intermediate penetrance 
genes, such as CHEK2, ATM, PALB214, which represent 2-3% of breast cancer cases. Today the 
research activities are focus on the role of Single Nucleotide Polymorphisms (SNPs) (Michailidou 
et al, 2013). 
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MENSTRUAL AND REPRODUCTIVE FACTORS: The larger the fertility window, the higher 
the probability of developing breast cancer. In this sense a late menarche and an early menopause 
had a protective effect (Kelsey et al, 1993; Colditz and Rosner, 2000). Nulliparity, a first full-term 
pregnancy in late age and failure to breastfeed are associated with an increased risk (Colditz and 
Rosner, 2000). In particular, the relative risk of breast cancer is reduced by 7% for each full-term 
pregnancy and 4.3% for each year of breastfeeding. 
HORMONAL FACTORS: The higher the levels of circulating estrogens and the longer the 
glandular epithelium of the breast is exposed to them, the greater the risk of developing breast 
cancer is (Rovera et al, 2018). The literature of the last 20 years on the association between 
hormone replacement therapy (HRT) and breast cancer is very extensive and articulated (ESHRE 
Capri Workshop Group, 2004; Moskowitz et al, 2014). Users of hormonal contraceptives have a 
modest increase in the likelihood of illness compared to non-users and this risk returns to non-user 
population about 10 years after the suspension (Collaborative Group on Hormonal Factors in Breast 
Cancer, 1996). 
DIETARY AND METABOLIC FACTORS: A high consumption of animal fats and alcohol seems 
to be associated with the development of breast cancer (Rovera et al, 2018). Obesity and the 
metabolic syndrome are recognized risk factors, probably linked to the excessive presence of 
adipose tissue, the main source of estrogen in menopause (Rosato et al, 2011). Protective role is 
instead played by physical education (Gonçalves et al, 2014). 
RADIATION EXPOSURE: Women exposed to radiation therapy in the thoracic district, especially 
if at a young age, have a higher frequency of breast cancer (Clemons et al, 2000). The risk of 
disease increases proportionally to the amount of radiation received and to the earliness of the 
exposure (Moskowitz et al, 2014). 
PRECANCEROUS LESIONS: A condition of epithelial hyperplasia without atypia is associated to 
a 1.5 to 2 times greater risk of developing a carcinoma. In atypical ductal or lobular hyperplasia this 
risk becomes 4-5 times greater. Atypical hyperplasia, in fact, is a clonal proliferation with the same 
histological features of carcinoma in situ, but smaller or equal in size to 2mm. 
 
2.2	Molecular	classification	
	
The immunohistochemical analysis performed on the specimen allows an evaluation of the 
expression of: 
Hormonal receptors: estrogen receptors (ER), and progesterone receptors (PgR). 
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Ki67: nuclear protein encoded by the MKI67 gene. It is used to estimate the growth fraction of the 
neoplasm. 
HER2: receptor tyrosine kinase responsible for the control of cell growth, survival and proliferation. 
Its activation therefore promotes tumor growth.  
According to the San Gallen Consensus of 2013, breast cancers can be divided into five molecular 
subtypes according to their receptor status and gene expression profile. Each subtype is 
characterized by a specific prognosis and response to therapy: 
Luminal A (40-55%): it is usually associated with a better prognosis. These tumors express 
hormonal receptors but not HER2. These tumors express ER, PgR> 20% and Ki67 <20% (Ahn et 
al, 2013); they are generally well-differentiated with a low proliferative index and strongly 
responsive to hormonotherapy. 
Luminal B HER2-negative (6-10%): although they express ER, these carcinomas express PgR 
<20% or Ki67> 20%; they are less differentiated and may benefit from chemotherapy as well as 
hormone therapy. 
Luminal B HER2-positive (15-20%): they are positive to hormonal receptors, overexpress HER2 
regardless of the proliferation index and they are of medium-high grade; they also benefit from 
monoclonal antibody therapy. 
HER2-positive (non-luminal, 7-12%): overexpression of HER2 but no hormonal receptors, 
generally poorly differentiated, highly proliferating and associated to high risk of metastasis. 
Triple negative (13-25%): do not express either hormonal receptors or HER2. They generally have 
a high proliferative index (> 50%) and a good response to chemotherapy. 
 
2.3	Therapy	
 
The association between surgery and radiotherapy is the gold standard in conservative treatment of 
invasive breast cancer, in order to eliminate any foci of residual tumor cells after surgery. Indeed, 
radiotherapy after conservative surgery strongly impacts the risk of local recurrence (Truong et al, 
2006; EBCTCG et al, 2014). 
Radiation therapy can lead to acute (asthenia, skin erythema, epidemiolysis) or late toxicity 
(hardening and retraction of the breast, cutaneous dystrophy, telangiectasia, lymphedema of the 
arm) (Hickey et al, 2016; Coen et al, 2003). 
Pharmacological approaches to breast cancer vary based on molecular characterization of the 
tumour. It can be divided into hormonal therapy, chemotherapy and targeted therapy, depending on 
the target affected by drugs. 
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Hormonal therapy may be used for patients with hormone-responsive breast cancer (i.e. with ER 
expression ≥ 1% or PgR ≥ 1%) (EBCTCG 2005). These tumors (Luminal A and B) are the most 
frequent in all age groups and particularly in older women (Clarke et al, 2012). The side effects of 
these drugs include sudden hot flushes, fluid retention and mood changes; less frequently it can be 
observed thromboembolic phenomena or an increased incidence of endometrial tumour (Zervoudis 
et al, 2010). 
Chemotherapy treatment can be neoadjuvant or adjuvant. Neoadjuvant chemotherapy precedes 
surgery. It is generally used in the case of locally advanced carcinoma (Locally Advanced Breast 
Cancer, LABC) and its primary objectives are: obtain a downstaging of the neoplasia and control 
distant micrometastases through an early "sterilization" of the whole organism. This treatment aims 
to achieve a complete response to improving the patient's prognosis. 
Adjuvant chemotherapy, on the other hand, aims to reduce the risk of loco-regional recurrence. 
Generally, a drug association (polychemotherapy) is used for 6 months (EBCTCG 2005). The most 
widely used drugs are anthracyclines and taxanes. 
In case of metastatic disease, it is generally more appropriate to proceed immediately with 
chemotherapy and to rely on surgical therapy only in selected cases, when a full remission of the 
metastatic lesion is obtained for at least 6-12 months with permanence of the primitive carcinoma. 
Among the toxicities related to cytotoxic chemotherapy, particularly important is leuko-neutropenia 
and chemo-induced amenorrhea (CIA) (Zervoudis et al, 2010; Sonmezer et al, 2006). 
More than 20% of breast carcinomas express the HER2 protein (Santa-Maria et al, 2016), thus can 
be treated with targeted therapy. Although this characteristic is generally associated with 
unfavorable immunohistochemical characteristics, such as the lack of hormonal receptor 
expression, it has a further specific therapeutical perspective. This is represented by trastuzumab: 
monoclonal antibody drug able to selectively act on HER2 receptors (Moasser et al, 2015; Ahmed 
et al, 2015; Figueroa-Magalhães et al, 2014). 
 
2.4	Homologous	Recombination	Deficency	(HRD)	in	Breast	Cancer	
 
DNA repair pathways represent a tightly controlled network protecting cells from exogenous and 
endogenous DNA damage. These pathways are frequently aberrant in cancer cells, leading to the 
accumulation of DNA damage and genomic instability. BRCA1 and BRCA2 genes are the most 
known and are associated with hereditary breast and ovarian cancer; they play an important role in 
the process of DNA repair.  
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This highly conserved pathway is involved in double-strand DNA break repair by the process of 
homologous recombination (HR). The base excision repair pathway is a second highly conserved 
repair process involved in single-strand DNA breaks. Poly (ADP-ribose) polymerase (PARP) 
enzymes play an important role in this pathway. 
PARP is important for resolving stalled replication forks, and its inhibition during base excision 
repair requires BRCA-dependent HR to resolve (Helleday, 2011; Ray Chaudhuri et al, 2016). 
Targeting DNA damage response pathways has emerged as an attractive strategy to destabilize 
tumor genomic integrity and trigger genomic catastrophe and cell death in a tumor-specific fashion. 
The role of BRCA1/BRCA2 in double-strand DNA repair via HR has been well documented (Krejci 
et al, 2012), and there is mounting evidence that breast cancers arising in BRCA1/BRCA2 germline 
mutation carriers respond favorably to therapies that target DNA repair pathways, such as platinum 
salts and PARP inhibitors (PARPis) (vonMinckwitz et al, 2014; Sikov et al, 2015; Tutt et al, 2015). 
Some sporadic breast cancers also harbor defects involving the HR pathway and respond similarly 
to platinum salts. It is also hypothesized that some sporadic breast cancers with defects in the HR 
pathway may benefit from the addition of PARPis to standard therapies (Wendie et al, 2017). These 
sporadic breast tumors are commonly referred to as being BRCA-like and are often associated with 
TNBC. It is estimated that up to 40% (Akashi-Tanaka et al, 2015) of familial and sporadic breast 
cancers are HR deficient (HRD). 
Current research has focused on the development of a companion diagnostic to identify sporadic 
BRCA-like tumors that would allow clinicians to identify those patients who may benefit from 
drugs targeting DNA repair path- ways and to spare those who are unlikely to benefit. 
Tests of HRD focus on either the detection of the underlying driver mutations responsible for the 
HR defect or the resultant mutational landscape of deficient HR inferred by nonspecific collateral 
damage to the genome (Fig 7). 
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Fig. 7: possible driver modifications responsible for HR defects. 
 
Driver germline (inherited) or somatic (acquired) mutations may take the form of sequence or 
structural variants that generally result in loss of function or aberrant functioning of BRCA1/ 
BRCA2 or other genes encoding members of the HR pathway. 
2.5	TESTS	OF	DRIVER	MUTATIONS	
	
Sequence variants (or mutations) include substitutions, deletions, or insertions of nucleotides (Fig 
7A). Those that occur within genes may result in pathogenic protein abnormalities. The genes and 
their protein products involved in HR are numerous, and their interactions are complex. 
 
2.5.1	Germline	Mutations	in	HR-Associated	Genes	
	
In addition to germline BRCA1/BRCA2 mutations, clinical genetic testing panels now include a 
number of proposed breast cancer predisposition genes, although not all of these genes have de- 
finitively been shown to increase breast cancer risk. Other hereditary predisposition genes involved 
in HR that are proven to be moderate to high risk include PALB2, ATM, and CHEK2. More 
recently, BARD1 and RAD51D have been shown to increase breast cancer risk, whereas some genes 
(NBN, MRE11A, RAD50, RAD51C, BRIP1) are unlikely or confirmed not to increase breast cancer 
risk (Couch et al, 2016). 
It is not clear if breast cancers arising from these germline mutations are as sensitive to DNA-
damaging therapies as BRCA1/BRCA2-mutated breast cancers (Lord and Ashworth, 2016). 
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2.5.2	Somatic	Mutations	in	HR	Genes	
	
Somatic mutations may also arise in genes involved in HR. Somatic mutations in BRCA1/ BRCA2 
occur in approximately 2.5% of all sporadic breast cancers (Nik-Zainal et al, 2016). It is 
hypothesized that somatic BRCA1/BRCA2-mutated breast cancers will respond similarly to DNA-
damaging therapies, but it is not definitively known if germline and somatic BRCA1/BRCA2 
mutations are biologically equivalent. Next-generation sequencing studies (Nik-Zainal et al, 2016; 
Hennessy et al, 2010; Winter et al, 2016; Shah et al, 2012) continue to expand the list of genes 
involved in breast cancer, and this list includes HR genes. The extent to which these HR genes drive 
tumor genesis continues to be explored. 
Looking beyond germline BRCA1/BRCA2 mutations has implications in terms of choosing patients 
who stand to benefit from DNA-damaging therapies, most notably PARPis. How this can be 
achieved is not certain. It is possible that HRD status will be a better predictor of PARPi response in 
breast cancer.  
 
2.5.3	Copy	Number	Aberrations	
	
Copy number aberration/alteration (CNA) refers to acquired changes in copy number of genes in 
tissue, such as tumor, whereas copy number variant (CNV) refers to changes in copy number of 
genes in the germline, affecting all cells in an individual. CNVs may also be reported in cancer, 
although they are usually qualified with the term acquired as compared with constitutional, so as to 
differentiate between the somatic and germline settings. In contrast to entire chromosome number 
gains or losses, CNA/CNVs are on a much smaller, generally submicroscopic, scale, with the size 
of DNA copy-number alterations (gain or loss) being > 1 kb in length (Fig 7C). Although the extent 
to which CNAs contribute to tumorigenesis is not entirely known, some of the well-established 
driver events in cancer are CNAs (eg, Myc, HER2, Cyclin D1). Furthermore, an increased burden 
of CNAs is associated with higher genomic instability and subsequent malignant transformation 
(Bergamaschi et al, 2006). 
 
2.5.4	Structural	Rearrangements	
	
Inversions, translocations, and recombination change the location or orientation of a DNA sequence 
(Watkins et al, 2014). Translocations result in the exchange of DNA between non homologous 
regions of DNA. Inversions result in the change of orientation of a segment of DNA. 
Recombination results in exchange of DNA between homologous regions of DNA, and this 
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structural rearrangement may lead to loss of heterozygosity (LOH), a gross chromosomal event that 
results in the loss of entire genes (eg, BRCA1, BRCA2). Two types of acquired LOH are important 
to note: deletion LOH, where there is a copy number loss; and copy number–neutral LOH, where 
the absolute copy number remains the same (Fig 7D). Both deletion and copy number– neutral 
LOH, as with CNAs, lead to allelic imbalance that can be inferred by studying single- nucleotide 
common variation across the genome (single-nucleotide polymorphism (SNP) analysis); this may 
be in the form of other types of DNA microarrays that may be fully or partially based on SNP 
probes across the genome. 
Three tests of structural rearrangements have come to the forefront: telomeric allelic imbalance 
(TAI), large-scale transition (LST), and LOH. 
TAI was developed using a SNP genotype array platform (Birkbak et al, 2012) to detect the number 
of chromosomal regions with allelic imbalance extending to the subtelomere, a common genomic 
abnormality that leads to an unequal contribution of maternal and paternal DNA sequence but does 
not necessarily change overall DNA copy number. Break points of TAI regions were nonrandom 
and enriched for CNVs, which results in an imbalance and then leads to HRD, which may result in 
platinum sensitivity in the way that BRCA1 associated cancer responds. Allelic imbalance was the 
best predictor of cisplatin sensitivity after identifying associations between a variety of 
subchromosomal abnormalities and cisplatin sensitivity. 
LST measures chromosomal breaks between adjacent chromosomal regions of at least 10 Mb. 
LOH measures the number of LOH regions > 15 Mb and less than a whole chromosome and was 
recognized as a discriminatory assay in two independent data sets of ovarian tumors (Abkevich et 
al, 2012). A composite index of all three markers called the homologous recombination deficiency 
(HRD) assay was developed which has been shown to have better sensitivity than the individual 
scores in predicting HR deficiency (Timms et al, 2014). 
While Triple Negative Breast Cancer (TNBC) is heterogeneous, a significant portion of TNBC is 
characterized by defective homologous recombination (HR) (Lord and Ashworth, 2016; Telli et al, 
2018). Homologous recombination is a high- fidelity DNA repair mechanism that is critical for 
efficient repair of double-strand DNA breaks. While this is a sentient feature of BRCA1/2 mutated 
breast cancer, defects in HR are common in a larger group of TNBCs as well. Germline BRCA1 
and BRCA2 mutations are present in approximately 14–20% of TNBCs, a significantly larger 
percentage of patients have been reported to harbor HR defects (Lord and Ashworth, 2016; Telli et 
al, 2015). 
Clinical identification of HR deficiency at the time of diagnosis is currently being actively 
investigated for its potential to guide optimal therapy selection in TNBC patients. 
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Although the primary focus is on TNBC, the role of HRD in many other tumor types is emerging as 
an important target. BRCA1 and BRCA2 mutations are the archetype of HR-deficient tumors and 
have provided insight into other causes of HRD. Developing a reliable biomarker will be key to 
identifying patients with HRD tumors who may benefit from HRD-targeted therapies. 
 
In contrast to genomic tests that characterize the mutations in HR pathway genes or characterize the 
mutational landscapes of HRD tumors, functional measures of HR pathway deficiency provide the 
most direct evidence of an HR pathway defect.  
 
2.6	Breast	Cancer	Genes		
 
Family linkage studies have identified high-penetrance genes, BRCA1, BRCA2, PTEN and TP53, 
which are responsible for inherited syndromes. Moreover, a combination of family-based and 
population-based approaches indicated that genes involved in DNA repair, such as CHEK2, ATM, 
BRIP1 (FANCJ), PALB2 (FANCN) and RAD51C (FANCO), are associated with moderate BC 
risk. 
Breast cancer predisposition today can be attributed to several levels of genetic susceptibility: rare 
high-risk alleles, conferring a risk more than five and up to 20 times as high as the risk among the 
general population; rare moderate-risk alleles with a relative risk greater than 1.5 and lower than 5, 
and common low-risk alleles conferring risks between 1.01 and 1.5 of the general population. 
Whereas high-risk genes may be identified by traditional linkage analysis of genetic markers in BC 
families, discovering moderate and low risk BC genes requires a different approach. 
Most of these variants occur with high frequency and they have a significant impact on the BC risk. 
 
2.6.1	High-risk	inherited	syndrome	genes	
	
Hereditary breast and ovarian cancer syndrome (HBOC) is a highly penetrant autosomal dominant 
disorder. It is caused by an inherited germline mutation in cancer susceptibility genes, BRCA1 or 
BRCA2. BRCA1 was cloned in 1994 following a long search for the gene using linkage analysis 
and maps on chromosome 17q21. This was closely followed by discovery of BRCA2 on 
chromosome 13q12–13 in 1995. They are both classic tumour suppressor genes, which are involved 
in the maintenance of genomic stability by facilitating DNA repair, primarily executing DNA 
double-strand break repair by homologous recombination (HR). Despite of BRCA1 and BRCA2 
initially appearing to be genes with similar functions, it is now clear that these two genes are 
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different in terms of their molecular biology, protein interactions and the cancer risks they confer. 
BRCA1 associates with multiple repair proteins and cell cycle regulators, being capable of forming 
multiple protein complexes, which contribute to its role in maintaining chromosome stability and 
tumour suppression. BRCA1 is a substrate of the central DNA damage response kinases ATM 
(ataxia telangiectasia mutated) and ATR (ataxia telangiectasia and Rad3-related protein) that 
control the DNA damage response. BRCA1 is required for homology directed repair, a pathway 
that facilitates error-free repair of double-strand breaks (DSBs) and resolution of stalled DNA 
replication forks through HR, as well as post-replicative repair in response to UV damage. BRCA1 
also regulates the transcription of several genes in cancer including ATM, and homeostasis of itself 
so that levels remain capable of maintaining genome integrity in response to genotoxic insult. 
BRCA2 primary function is in HR and it is based upon its ability to bind to the strand invasion 
recombinase RAD51. BRCA2 contains eight BRCT repeats, each of which can bind and recruit 
RAD51 to sites of DNA damage. BRCA2 also interacts with PALB2, through which it localizes to 
DSBs together with BRCA1. 
BRCA1 and BRCA2 are involved in maintaining genome integrity, at least in part, by engaging in 
DNA repair, cell cycle checkpoint control and even the regulation of key mitotic or cell division 
steps. Thus, the complete loss of function of either protein leads to a dramatic increase in genomic 
instability.  
The estimated BRCA1 and BRCA2 mutation carrier frequencies in the general population are 
between 1 in 300 and 1 in 800. 
TP53 was first identified in 1979 and it is now the most common altered gene in solid tumours. P53 
is essential in cell-cycle control, resulting in either a delay in cell-cycle progression or apoptosis. 
Inherited germline mutations are rare. However, they are known to result in Li-Fraumeni syndrome 
(LFS). LFS causes childhood tumours: soft tissue, osteosarcomas, gliomas, adrenocortical 
carcinoma, and very early onset BC. Over 70% of classical LFS families inherited TP53 mutations. 
LFS only accounts for less than 0.1% of BC, but mutations in TP53 confer an 18- to 60-fold 
increased risk of BC under the age of 45 years old compared to the general population. 
 
2.6.2	Moderate	breast	cancer	risk	alleles	
	
CHEK2	
	
Germline CHEK2 (checkpoint kinase 2) sequence variants have been reported in families with LFS 
that do not carry TP53 mutations. CHEK2 encodes a cell cycle checkpoint kinase implicated in 
DNA repair. CHEK2 emerged from the sequencing of plausible candidate genes in families with 
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multiple cases of BC families without BRCA1/2 mutations. Its association with increased BC risk 
has been explored in many studies since 2002, and nowadays, its significance has been 
demonstrated with a high statistical degree. 
A particular germline mutation CHEK2 1100delC, has been associated with a two-fold to three-fold 
increase in BC risk. Many large studies have reported this finding. In 2008, a meta-analysis of 
studies assessing CHEK2 risk in populations of northern and eastern European descendent, 
calculated odds ratios for BC in unselected populations, early-onset BC, and familial BC. For early-
onset BC, the study estimated an OR of 2.6 (95% CI 1.3–5.5) and also found that for patients 
selected from a population with familial BC, CHEK2 1100delC heterozygotes had a much higher 
OR 4.8 (95% CI 3.3–7.2). CHEK2 mutation carriers either with a strong family history of BC or a 
history of bilateral disease was found to be at comparable risk to BRCA carriers with an estimated 
lifetime risk of 37% and 59% respectively. 
These results suggest that CHEK2 1100delC screening should be considered in patients with a 
strong family history of BC. 
 
ATM	
	
Biallelic mutations in Ataxia telangiectasiamutated (ATM) gene cause the autosomal recessive 
disease Ataxia-telangiectasia (AT). This is a neurodegenerative disorder that is characterized by 
cerebellar ataxia, telangiectases, immunodeficiency, hypersensitivity to ionizing radiation and 
approximately 100 times increased risk of cancer. ATM is a protein kinase involved in the response 
to DSBs in a pathway that includes TP53, BRCA1 and CHEK2. DSBs activate ATM, which in 
turns, activates the full DNA damage response. Heterozygous ATM mutation carriers, found in 
approximately 0.5–1.4% of the general population, do not display the symptoms observed in 
patients. However, several studies have shown an increased risk of cancer in them: tumours of 
breast, pancreas, stomach, bladder, ovary, and chronic lymphocytic leukaemia. 
Extensive research has been carried out into the association of ATM mutations and BC, showing 
that up to 13% of BC may be due to heterozygous ATM mutations. The relative risk of BC in 
heterozygous ATM female carriers has been estimated in 2.37 (95% CI, 1.51–3.78) that of the 
general population. Moreover, it has been described that ATM mutations are more frequent in BC 
patients selected on the basis of a family history of BC than from those compared to unselected 
patients. 
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MRN	(MRE11–RAD50–NBS1)	COMPLEX	
	
The MRN complex is composed of three proteins, MRE11, RAD50 and NBS1. It binds to damaged 
DNA and undergoes a series of conformational changes to activate and increase ATM affinity for 
its substrates and retain active ATM at sites of DSBs. MRN complex plays a key role in DNA 
damage detection and activation of the ATM kinase. 
Mutations in all three members of the MRN complex have been noted in human cancers. Mutations 
of MRE11, NBS1 and RAD50 manifest as ataxiatelangiectasia-like disorder (ATL), Nijmegen 
breakage syndrome (NBS) and NBS-like disorder, respectively. Unsurprisingly, carriers of MRE11, 
NBS1 and RAD50 mutations have been implicated in BC.  
Screening for mutations in all the three MRN genes in Finnish population discovered a founder 
mutation in RAD50 associated with a 4.3-fold increase in BC predisposition (OR 4.3, 95% CI 1.5–
12.5). However, this mutation has not yet been found in any other populations, including other 
Nordic states, making difficult the confirmation of this association. 
 
FANC	FAMILY	
	
Fanconi anaemia (FA) is a genetic disease characterized by progressive aplastic anemia, multiple 
congenital defects, and susceptibility to both hematologic and solid malignancies. A defect in any 
of the proteins along the FA pathway prevents cells from repairing interstrand crosslinks and 
predisposes them to chromosomal breakage and cell death. The relationship between FA and BC 
susceptibility did not become fully apparent until it was discovered that BRCA2 and FANCD1 were 
two different names for the same gene. 
Constitutional inactivating mutations in genes responsible for FA have been clearly associated with 
an increased susceptibility to both BC and OC and include the genes BRCA2 (FANCD1), FANCN 
(PALB2) and FANCJ (BRIP1). One third of patients homozygous for a FA gene mutation will 
develop cancer by the age of 40 years old. These included squamous cancer of the head and neck, 
meduloblastomas, oesophageal and skin cancers, gynecological cancers, as well as liver and kidney 
tumours. Strong associations exist between heterozygous mutations of BRCA2/FANCD1 and breast 
and/or ovarian cancer development, as described in BRCA1/BRCA2 families. However, 
heterozygous mutations in other FA genes have also been shown to be associated with an increased 
risk of BC. Evidence that other FA pathwayrelated proteins were also BC susceptibility genes did 
not unfold until BRIP1 was identified in FANC-J patients. FANCJ, also known as BACH1 or 
BRIP1, is a BRCA1-associated DEAH helicase involved in translesion synthesis helping the 
polymerase bypass the interstrand crosslink, placing its role distal to the monoubiquitinated 
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FANCD2 of the FA pathway. BRCA1–FANCJ interaction is essential for promoting error-free 
repair, checkpoint control and for limiting DNA damage tolerance. The most common germline 
FANCJ/BRIP1 mutant allele is found both in BC and FA patients. In 2006, truncating mutations in 
BRIP1 were identified in BC families. Segregation analysis assessed a Relative Risk (RR) of BC of 
2.0 (95% CI 1.2–3.2), that increased to 3.5 (95% CI 1.9–5.7) for carriers younger than 50 years old. 
The discovery of another BC predisposition gene in the FA pathway PALB2 or FANCN, suggests 
that proteins acting downstream of monoubiquitinated FANCD2 and FANCI increase the risk of 
BC, while those acting upstream do not. The role of PALB2 in homologous repair is to behave as a 
protein that functionally bridges BRCA1 and BRCA2 and also cooperates with RAD51 to stimulate 
recombination. Biallelic PALB2 mutations have been described as responsible for FA subtype 
FANCN. Research on BC families without BRCA1/2 mutations resulted in identifying PALB2 
mutations. However the PALB2 mutations rarity makes accurate estimation of its penetrance more 
difficult. A familial-based case-control association study of PALB2 showed that a monoallelic 
mutation confers an OR of 2.3 (95% CI 1.4–3.9) for BC. As with BRCA2 heterozygotes, PALB2 
mutations have been associated with an increased risk of pancreatic cancer. 
 
RAD51	FAMILY	
	
The RAD51 family consists of several proteins, which preferentially bind to single-stranded DNA, 
and form complexes with each other. RAD51 unwinds duplex DNA and forms helical 
nucleoprotein filaments at the site of a DNA break. BRCA2 stimulates RAD51-dependent strand 
exchange. RAD51C was discovered to be the cause of a Fanconi-like disorder and is a new cancer 
susceptibility gene. Six clearly pathogenic mutations were found among 1,100 breast/ovarian cancer 
families. The mutations were found exclusively within 480 pedigrees with the occurrence of both 
breast and ovarian tumors and not in 620 pedigrees with breast cancer only or in 2,912 healthy 
controls. This is distinctive behaviour from the situation observed with monoallelic mutations in the 
FA-related genes PALB2 and BRIP1, which are rarely present with OC. What it is even more 
striking, is that apparently there was complete segregation of the mutations to affected individuals, 
suggesting a penetrance level similar to BRCA1/2. Recently, a mutational screening of the 
RAD51C gene in a large series of 785 Spanish breast and/or ovarian cancer families identified 1.3% 
of mutations, and suggested the inclusion of the genetic testing of RAD51C into the clinical setting. 
Investigators have recently sequenced RAD51D in 911 wild-type BRCA1/2 breast-ovarian cancer 
families as well as 1,060 population controls. Inactivating mutations were identified in 8 in 911 
breast and ovarian cancer families (0.9%), 0 in 737 BC families, and 1 in 1060 controls (0.09%). 
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There was a higher prevalence of mutations present in families with more cases of OC. The RR of 
OC for carriers of deleterious RAD51D mutations was estimated at 6.3 (95% CI 2.86–13.85) 
whereas RR of BC was non-significantly increased. New data support the previous observation that 
loss-of-function mutations in RAD51D predispose to OC but do not to BC. 
The XRCC2 and XRCC3, members of RAD51 family, maintain chromosomal stability during HR. 
A homozygous frameshift mutation in XRCC2 being associated with a previously unrecognized 
form of FA was recently reported. XRCC2 binds directly to the C-terminal portion of the product of 
the BC susceptibility pathway gene RAD51, which is central to HR. XRCC2 also complexes in 
vivo with RAD51B (RAD51L1), the product of the breast and ovarian cancer susceptibility gene 
RAD51C9 and with the product of the OC risk gene RAD51D, and localizes together on sites of 
DNA damage. An exome-sequencing study of families with multiple BC individuals identified two 
families with XRCC2 mutations, one of them with a protein-truncating mutation and the other one 
with a probably deleterious missense mutation. From other XRCC genes investigated, XRCC1 
399Gln allele acts as a recessive allele in association with BC risk. 
 
BREAST	CANCER	LOW-RISK	ALLELES	
	
Part of the unexplained fraction of familial relative risk is likely to be explained by a polygenic 
model involving a combination of many individual variants with weak associations to risk, the so 
called low-penetrance polymorphisms. 
The frequency of these alleles may range from 5% to 50% and could possibly be higher in families 
with BC. Individually they only have a small effect on BC risk (relative risk ≥1.01 and <1.5). 
Nevertheless, they may collectively account for a large component of BC heritability. 
Other identified loci associated with BC in large studies involving thousands of subjects are, 
MAP3K1 (mitogen-activated kinase 1), LSP1 (lymphocytespecific protein), and TNRC9 
(trinucleotide repeatcontaining 9), along with a 110 kb region of chromosome 8q24. Associations 
with other chromosomal regions, 2q35, 5p12, 6q22, and 16q12, also have been reported. Further 
analysis showed that allelic variation at FGFR2, TNRC9, 8q24, 2q35, and 5p12 are associated with 
physiological characteristics of breast tumours, such as ER status. Moreover, it has been shown that 
specific FGFR2, MAP3K1, and TNRC9 variants may interact with BRCA1 and BRCA2 mutations 
to increase BC risk. 
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3	The	human	blood	microbiome	and	septic	risk	
3.1	The	human	blood	microbiome	(HBM)	
	
In the last decades several studies focused on microbiome, i.e. the analysis of the entire DNA 
content of microorganisms living in our body. 
More recently, scientists suggest the possibility of the existence of a “healthy” human blood-
microbiome (HBM), in contrast with the previous concept of blood as a sterile tissue. 
The first report of bacteria in blood dates back to 1674, when Antonie van Leeuwenhoek observed 
bacteria together with erythrocytes in salmon blood (Bessis and Delpech, 1981). In 1969, Tedeschi 
and colleagues firstly suggested the possible presence of mycoplasma-like or L-phase bacteria, i.e. 
bacteria without the cell wall, in blood of healthy individuals (Tedeschi et al, 1969). 
The possibility to identify the presence of bacteria with a 16S qPCR pushed forward the analysis on 
HBM, and from 2000 several publications described the presence of bacteria in blood of healthy 
people (Nikkari et al, 2001; McLaughlin et al, 2002; Amar et al, 2013). 
It has been demonstrated that in some pathological conditions, such as cirrhosis, inflammatory or 
cardiovascular diseases, sepsis or diabetes, bacteria probably originating from the gut can cross the 
gut wall and migrate toward tissues (Potgieter et al, 2015; Manzo et al, 2015; Amar et al, 2011; 
Amar et al, 2013; Wang et al, 2015; Bellot et al, 2010). 
In 2016 Païsse and colleagues described in details blood microbiome of 30 healthy individuals, 
evidencing the presence of a diversified microbiome that can be implied in transfusion-transmitted 
bacterial infections. In this work, they performed a 16S rDNA quantification by real time qPCR and 
a targeted 16S metagenomic sequencing of the V3-V4 hypervariable region on whole blood and its 
fractions, i.e. plasma, buffy coat and red blood cells (Païsse et al, 2016). 
The first approach resulted in a differential distribution of bacterial DNA between blood fractions 
and individuals: they observed a strong correlation between white blood cells concentration and 16S 
DNA copy values in the buffy coat, suggesting a constant average quantity of bacterial DNA per 
immune cell, while the main difference between bacterial DNA among individuals was observed in 
the red blood cell compartment (Païsse et al, 2016). 
Bacterial profiles obtained with the metagenomic analysis described that the Proteobacteria phylum 
was the most represented, followed by the Actinobacteria one, while Firmicutes and Bacteroidetes 
phyla are less represented, differently from what is observed in gut microbiota (Païsse et al, 2016). 
Taken together, these data represent the first comprehensive description of the HBM in healthy 
donors. 
Further analysis revealed how HBM diversity is affected in some pathological conditions: Traykova 
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and colleagues, targeting the 16S gene by qPCR, evidenced an increased number of bacterial 
species and DNA in patients affected by cirrhosis (Traykova et al, 2017); higher number of 16S 
DNA gene copies was observed also in patients with severe acute pancreatitis, with an increase in 
Bacteroides and Actinobacteria compared to healty controls (Li et al, 2018); an interesting study 
conducted in type-2 diabetes affected patients associated an increased risk in developing diabetes in 
people ‘carrying’ the Sediminibacterium genus, while those presenting the Bacteroides genus 
showed a lower risk (Qui et al, 2019). 
Bacterial DNA in blood can be used as a powerful marker in several clinical settings. Bossola and 
colleagues associated the presence of bacterial-derived DNA fragments in blood of patients 
undergoing chronic haemodialysis with increased levels of C-reactive protein and interleukin 6 (IL-
6), two well known markers of inflammation, a typical condition associated with maintenance 
haemodyalisys (Bossola et al, 2008). Simimlarly, in 2013 the abundance of bacterial-derived DNA 
in blood of patients subjected to peritoneal dialysis correlates to the systemic inflammatory status, 
only hypothesizing the possible use of bacterial-derived DNA as a prognostic marker of renal 
failure (Kwan et al, 2013). 
All these works analysed DNA extracted from whole blood or its fractions, thus considering live, 
dormant and/or dead bacteria, either free circulating and associated with blood cells. A couple of 
works focused on circulating cell-free DNA as the unique source of information. 
A first study on lung transplanted patients aimed to set up a diagnostic assay able to monitor 
simultaneously rejection and infection status by performing shotgun sequencing of cfDNA followed 
by identification of donor-derived single nucleotide polymorphisms (SNPs) and nonhuman cfDNA 
sequences (De Vlaminck et al, 2015). They observed a good correlation between donor-derived 
cfDNA and clinical indicators of graft dysfunction, such as pulmonary function tests or tests for 
cytomegalovirus, that is strictly associated to allograft injury (De Vlaminck et al, 2015). 
The analysis of nonhuman sequences revealed cases of undiagnosed infection among patient tested 
associated to pathogens, such as human herpesviruses and adenoviruses, which are not always 
tested. These data taken together suggest the utility to utilize cfDNA as a monitoring marker for 
multiple parallel analysis, such as detection of broad spectrum of infections and graft rejection (De 
Vlaminck et al, 2015). 
A further analysis of patients with different transplants (bone marrow, lung, heart) or pregnant 
women by shotgun sequencing of cell-free DNA identifyed novel contigs of DNA sequences with 
no to little homology in databases, suggesting the presence of uncharacterized and divergent 
microbes colonizing the human body. Interestingly, these contigs were observed in almost every 
sample analysed (Kowarsky et al, 2017). 
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Recently, a microbial cell-free DNA sequencing test, the Karius test, was validated clinically and 
analytically to identify and quantify 1250 bacteria, DNA viruses, fungi and eukaryotic parasites of 
clinical interest in a clinically relevant time (Blauwkamp et al, 2019). 
All these information lead us to the introduction of the concept of culture independent 
microbiology, i.e. the possibility microbial cfDNA furnishes to obtain information on microbes and 
drive clinician toward therapy without the need of cultures (Peaper and Durant, 2019). Several open 
questions need to be answered, such as which cutoff must be chosen to differentiate pathogens from 
nonpathogens, RNA-based assays to obtain information on clinically relevant RNA viruses, how to 
interpret multiple microbe identification or the lack of information on the localization of the 
infection (Peaper and Durant, 2019). 
3.2	Septic	risk	
	
In this perspective, we asked if cfDNA analysis and ‘liquid biopsy’ can be a monitoring tool in 
conditions in which no time course monitoring is possible. 
Patients with renal disease and that require dialysis are frequently affected by systemic infections 
that often lead to death (Sarnak and Jaber, 2000). Overwhelming uremia is surely one leading cause 
of the high number of infection because it is associated to alteration in host defence mechanisms 
(Naqvi and Collins, 2006). Sepsis and pneumonia are the most frequent infection in patient affected 
by chronic kidney disease (CKD). Haemodialysis patients are exposed to several infection risks, 
due to vascular access, such as central venous catheter, that plays an important role in bloodstream 
infection development (Naqvi and Collins, 2006). The main problem associated with sepsis in 
haemodialysis patients is that diagnosis is not so simple to be formulated. By now, possible septic 
patients are identified by the simultaneous presence of an infection and two or more systemic 
inflammatory response syndrome (SIRS) criteria (Abou Dagher et al. 2015). SIRS criteria are: a) 
temperature higher than 38°C or lower than 36°C; b) heart rate higher than 90 beats/min; c) 
respiratory rate higher than 20 breaths/min or PaCO2 lower than 32 torr; d) white blood cell counts 
higher than 12000 cells/mm
3 
or lower than 4000 cells/mm
3 
or the presence of more than 10% 
immature neutrophils (“band cells”) (Jaimes et al 2003). 
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4	Transplant	monitoring	
	
The possibility to monitor graft status by cfDNA analysis dates back to 1998, when Lo and 
colleagues performed a Y-specific PCR in women who had received liver or kidney transplant from 
a male donor (Lo et al, 1998), resembling the analysis performed on pregnant women with male 
foetuses one year before. Even if working, this approach was limited by the necessity to have a ‘Y-
free’ background and a ‘Y-positive’ graft. 
The discovery of Single Nucleotide Polymorphisms (SNPs) expanded monitoring possibility toward 
every transplant in which the donor and the recipient present variation in one or several SNPs. 
Several works take advantage of this characteristic to identify donor-derived cfDNA (dd-cfDNA) 
among recipient cfDNA in heart (Snyder et al, 2011; Beck et al, 2013; De Vlamink et al, 2014), 
liver (Beck et al, 2013) kidney (Beck et al, 2013; Bloom et al, 2016) or lung (De Vlaminck et al, 
2015). 
Both Snyder and Bloom observed how a 1% dd-cfDNA/recipient cfDNA corresponds to a normal 
graft status while increases in this ratio are significantly associated to active Ab mediated rejection 
(ABMR; Bloom et al, 2016) or an occurring organ rejection (Snyder et al, 2011). 
Beck and colleagues had the possibility to monitor dd-cfDNA dynamics from liver transplantation 
onwards, detecting a ~90% graft-derived cfDNA just after transplantation, falling down to <15% at 
day 10 in complication free patients or rising back to >60% in two patients with biopsy-proven 
rejection (Beck et al, 2013). 
Interestingly, the analysis on SNPs in cfDNA of heart transplanted patients performed by NGS 
sequencing revealed elevated dd-cfDNA even 5 months before moderate-to-severe rejection events, 
suggesting a powerful predicting ability not observed in concomitant biopsies (De Vlamink et al, 
2014). 
Analysis of dd-cfDNA can also be combined with other clinical parameters that indicate graft 
rejection, such as creatinine (Bloom et al, 2016) or Donor Specific Antibodies (DSA) to HLA 
antigens (Stanley et al, 2018) in kidney, in order to achieve a better evaluation of transplant status. 
We thus decided to verify the applicability of the AmpFlSTR® Identifiler® Plus PCR 
Amplification kit on the analysis of cfDNA in kidney transplanted patients, in order to monitor graft 
rejection events with a certified kit commonly used to genotype donor and recipient and determine 
their compatibility. 
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MATERIALS	AND	METHODS	
1	Validation	of	the	cfDNA	extraction	protocol	
1.1 Preanalytical	considerations	
	
Preanalytical	procedures	have	a	significant	impact	on	results,	accounting	for	46-68%	of	the	
error	rate	(Carraro	et	al,	2012;	Plebani,	2012).	This	data	suggest	the	necessity	of	standard	
operating	procedures	that	ensure	reproducible	results	among	different	source	area	and	
clinical	settings	(Basso	et	al,	2017).	
We	followed	indications	by	El	Massaoudi	and	colleagues	to	reduce	effects	on	cfDNA	
concentration	and	fragmentation:	plasma	as	a	source,	first	centrifugation	within	4h,	a	second	
high-speed	centrifugation	and	only	one	plasma	freeze-thaw	cycle,	if	necessary	(El	Massaoudi	
et	al,	2015).	
1.2	Samples	collection	
	
We firstly collect samples of patients with breast cancer, due to higher availability, to validate the 
cfDNA extraction protocol. Considering that patients presenting neoplasia bigger than 2 cm in 
diameter are not so common, we decided to perform this step including also samples with smaller 
tumours. 
Blood was collected from 13 patients with an average age of 62 yo (range 43-88 yo), neoplasia 
diameter of 15 mm on average (range 2-28 mm) and no BRCA 1-2 mutations. Data are summarized 
in Tab (see results). 
1.3	Blood	collection	and	plasma	isolation	
	
We collected 10 ml of peripheral blood in K3EDTA tubes commonly used for molecular 
applications. Plasma was isolated within 30 mins from the collection of blood in order to minimize 
the risk of white blood cells (WBCs) haemolysis. 
Plasma isolation was performed as follow: 
− Blood is firstly centrifuged at 1600 xg for 10 minutes to separate blood cells. 
− Supernatant is collected and transferred to 1.5 ml microcentrifuge tubes, being careful not to 
take away cells or proteins. 
− Supernatant is centrifuged again at 12000-16000 xg for 10 mins, in order to remove cellular 
debris. 
− Plasma is collected and transferred to new microcentrifuge tubes, being careful not to collect 
pellet formed at the bottom of the tube. 
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− The obtained plasma is processed immediately or stored at -80° C. 
We decided to exclude from the analysis all those samples that present any sign of haemolysis (i.e. 
those plasma whose colour show any shade of red). 
1.4	cfDNA	extraction	
	
We decided to firstly compare two different extraction procedures, both automatized, one working 
on the MaxWell® RSC (Promega) platform with the MaxWell® RSC ccfDNA Plasma Kit 
(Promega), and the other working on the Abbott m2000sp (Abbott). 
The extraction with MaxWell® RSC was done on 1 mL of plasma obtained as previously 
described. The quantification step was performed using both the fluorometer associated to the 
MaxWell@ RSC instrument and the Qubit™ dsDNA HS Kit (Thermo Fisher). The second 
extraction was performed on a volume of 300 µL of plasma and the quantification was performed 
with the Qubit™ dsDNA HS Kit (Thermo Fisher). 
Due to the limited amount of cfDNA obtained and to avoid the risk to consume all the material for 
just one analysis, we decided to evaluate extraction protocols that allow us to scale up the starting 
volume of plasma. 
We had the opportunity to test the NextPrep-Mag cfDNA isolation kit (Bioo Scientific) and the 
QIAamp MinElute ccfDNA Midi Kit (Qiagen), whose protocols allow to scale up the extraction till 
3 mL and from 3 to 10 mL of plasma, respectively. 
Both kits are based on magnetic beads purification of cfDNA. The Qiagen one uses beads to collect 
and concentrate cfDNA from plasma and then the purification is based on columns, while the Bioo 
Scientific kits requires the use of magnetic beads in all the steps of the protocol. We performed both 
protocols following manufacturer instructions. 
We validate the extraction protocols with samples from a different project and we decided to 
proceed with the QIAamp MinElute ccfDNA Midi Kit extracting from a starting volume of plasma 
of 4 ml. 
 
1.5	Preservative-containing	tubes	
 
We then test the utilization of the Blood STASIS 21-ccfDNA tubes (MagBio Genomics Inc.). These 
tubes are specific for cfDNA isolation due to the presence of an additive that stabilize cells and 
prevent coagulation, thus reducing the risk of genomic contamination by blood cell haemolysis and 
stabilizing cfDNA levels when stored for up to 21 days at room temperature. 
16 mL of blood were collected into 2 Blood STASIS tubes and centrifuged as described above. 
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We then extract in parallel cfDNA from plasma obtained from Blood STASIS 21-ccfDNA and 
common K3EDTA tubes with the QIAamp MinElute ccfDNA Midi Kit. 
Amount of cfDNA obtained from Blood STASIS 21-ccfDNA tubes was higher than K3EDTA ones, 
being equal the haemolysis of the plasma. 
We thus decided to proceed collecting samples in Blood STASIS 21-ccfDNA tubes. 
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EXPERIMENTAL	PROJECTS	
2	Breast	cancer	
2.1	Project	structure	and	inclusion	criteria	
 
This research project was submitted to the Ethics Commitee of the Circolo Varese Hospital and, 
after receiving the approval, we started enrolling patients with breast cancer who underwent surgery 
at the Senology Research Center - ASST Sette Laghi Varese. 
This is a monocentric, explorative and translational study. 
Inclusion criteria are: a) only female patients; b) cytologically or histologically confirmed breast 
cancer; c) candidate for surgery; d) no exclusion on the base of histological subtype or lymph node 
involvement; e) diameter size of the neoplasia:≥20mm; f) no previous detection of gene mutation 
(i.e. sporadic cancers, no BRCA1-2 mutated patients). 
Exclusion criteria consist of: a) previous breast cancer (i.e. recurrence); b) the patient has 
undergone treatments, either chemotherapy or radiotherapy. 
	
2.2	Sample	collection	and	plasma	separation	
	
We collected blood samples in Blood STASIS 21-cffDNA tubes and fresh tissue in culture medium 
from 19 patients that match including criteria indicated. 
Plasma has been separated as described in “blood collection and plasma isolation” paragraph. 
Fresh tissue has been placed in a culture media after surgery and then stored dry at -80°Cwithin 3 h. 
2.3	Genomic	DNA	extraction	
 
Genomic DNA has been extracted with the DNeasy Blood & Tissue Kit, starting from 25 mg of 
fresh tissue, following manufacturer instructions. 
The protocol consists of a first mechanical homogenization of the tissue followed by a Proteinase K 
digestion step and silica-based membrane purification with several centrifugations. 
DNA has been quantified with the Qubit dsDNA BR kit (Thermo Fisher) following manufacturer 
protocol. 
2.4	cfDNA	extraction	
 
Circulating DNA has been extracted as described in the paragraph 1.3. 
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2.5	Target	sequencing	procedure	
2.5.1	Genomic	DNA	
	
The preparation of genomic DNA, extracted from fresh tissue, was performed with the Homologous 
Recombination Solution by Sophia Genetics Kit (Sophia Genetics) and the Kapa™ Hyperplus 
Library preparation kit (Roche). These kits are usually used for formalin-fixed paraffin-embedded 
(FFPE) extracted DNA, characterized by DNA fragmentation and reduced molecule integrity. The 
usage of genomic DNA extracted from fresh tissue allows us to avoid these problems and have 
high-quality starting material. 
As suggested by the protocol, we used the maximum amount of DNA, i.e. 200 ng, to generate high-
quality sequencing data. 
200 ng of DNA in a 25 µl volume are firstly enzymatically fragmented at 37°C for 20 mins, then 
the End Repair and A-tailing (ER&AT) two step procedure is performed, with an incubation at 
20°C for 30 mins and a second at 65°C for 30 minutes. Fragments are then ligated to Dual Index 
Adapters and the reaction is cleaned up using AMPure XP magnetic beads to remove all the 
reagents of the previous reactions. 
Libraries this way prepared are then amplified with a PCR reaction whose conditions are 
summarized in the table below. Step 1st to 3
rd
 are repeated 8 times. 
 
 Temperature (°C) Time (s) 
Lid 99  
Initial step 98 45 
1
st 
step 98 15 
2
nd
 step 60 30 
3
rd
 step 72 30 
Final step 72 60 
Holding 10  
 
Amplified libraries are purified again with AMPure XP magnetic beads and individual libraries are 
quantified and their quality is evaluated. 
2 µl of the purified library is diluted with 6 µl of nuclease-free water, quantification is performed on 
2 µl of the diluted solution with a fluorometric method while quality control (QC) is performed by 
capillary electrophoresis and library profile should present fragments ranging between 200 bp and 
800 bp. 
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Libraries passing QC analysis are pooled mixing 300 ng of each library in a DNA low-binding tube; 
Blocking oligos and human Cot DNA are added to the mixture to mask adaptors and block 
nonspecific hybridization, respectively, and the mixture is lyophilized and stored at -20°C if not 
immediately utilized. 
Lyophilized libraries are resuspended in the Hybridation mix and hybridization step is performed as 
indicated by manufacturer (65°C for 4 to 16 hours). Streptavidin beads are used to bind and enrich 
hybridized targets by incubation at 65°C for 45 minutes. 
After a wash step to remove unbound DNA, the post-capture libraries are amplified. PCR 
conditions are listed in the table below. 
 
 Temperature (°C) Time (s) 
Lid 99  
Initial step 98 45 
1
st 
step 98 15 
2
nd
 step 60 30 
3
rd
 step 72 30 
Final step 72 60 
Holding 10  
 
Steps 1
st
 to 3
rd
 are repeated for 15 cycles. 
Post-capture amplified libraries are cleaned up with AMPure XP magnetic beads and purified 
libraries are checked for concentration and quality, as described in the previous step of control. 
The last step of the protocol consists in library preparation for sequencing. Molarity of each pool is 
determined by the ratio between library concentration (ng/µl) and the product of the average size 
(bp) and 649.5 (Fig. 8 below) multiplied for 10^6. 
 
 
Pools are sequenced on MiSeq platform. 
 
2.5.2	cfDNA	
	
	 46
The preparation of circulating DNA was performed following the Solid Tumour Solution by Sophia 
Genetics protocol for circulating cell-free DNA (Sophia Genetics) and the Kapa™ Hyperplus 
Library preparation kit (Roche). 
Compared to the protocol described for the genomic DNA, this one does not include the enzymatic 
fragmentation, due to the fragmented nature of cfDNA. 
We decided to use as much cfDNA as we have, in order to reduce the risk of having bad results in 
library preparation and sequencing. Considering the low amount of cfDNA, the first PCR was set to 
12 cycles. 
The protocol starts from the End Repair & A-tailing step (ER&AT) and follows the one previously 
described for genomic DNA. 
 
2.5.3	Data	analysis	
 
Data analysis was performed on the Sophia DDM® platform. A three-step procedure allows to 
rapidly and efficiently obtain information from row sequencing data. 
Step 1 consists in row data uploading and processing, resulting in a list of information. 
In step 2 results of step 1 are interpreted, thanks to the classification from highly pathogenic to 
benign made from the Sophia AI. 
Last step consists in a variant report definition. 
Variants detected were evaluated with the ClinVar (NCBI) database that allows a direct association 
between the variant and its role in health. 
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3	Septic	risk	
3.1	Project	structure	and	inclusion	criteria 
 
We enrolled patients undergoing dialysis and presenting clinical symptoms suggesting an 
emoculture analysis to verify the presence of bacterial systemic infection. 
Blood collection, plasma separation and cfDNA extraction have been performed as described in 1.2 
and 1.3. 
 
3.2	Library	preparation	and	sequencing	
	
Library preparation was performed following manufacturer indications and libraries passed quality 
control (QC) analysis. Shotgun sequencing was performed on a MiSeq v3 platform with these 
conditions: 2x150 bp, 10 million paired-end reads per sample. 
 
3.3	Metagenomic	analysis	
 
QC analysis on reads was evaluated in terms of phred score. Sequencing data with phred score 
above 20, indicating a good reliability of the base read, were sent to CosmosID® to be analysed. 
This company has curated and proprietary databases of 31064 bacterial, microbial and animal 
genomes. The ownership bioinformatics algorithms, summed to their database, allow them to finely 
determine strain level of microorganisms and to identify the presence of genes conferring resistance 
to antibiotics or coding for virulence factors. 
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4	Transplant	monitoring	
4.1	Project	structure	and	inclusion	criteria 
 
We started collecting blood samples from kidney-transplanted patients with clinical symptoms 
indicating a possible rejection event, thus directed to renal biopsy to evaluate graft status. 
Blood collection, plasma separation and cfDNA extraction have been performed as described in 1.2 
and 1.3. 
 
4.2	Detection	of	polymorphisms 
 
The analysis on microsatellite polymorphisms was performed with the AmpFlSTR® Identifiler® 
Plus PCR Amplification kit, that simultaneously amplify 15 microsatellite loci characterized by 
polymorphisms (Fig. 9). Each patient is analysed in parallel to DNA extracted from blood of the 
donor and of the recipient. 
	
Fig.	9:	list	of	microsatellites	and	relatives	polymorphisms	analysed	by	the	AmpFlSTR®	Identifiler®	Plus	PCR	
Amplification	kit.	
 
4.2.1	PCR	amplification	
 
	 49
PCR reaction was performed on 1ng cfDNA in 10 µL of TE buffer. The reaction consists of 10 µL 
cfDNA, 10 µL AmpFlSTR® Identifiler® Plus Master Mix and 5 µL AmpFlSTR® Identifiler® Plus 
Primer Set, that allows the amplification of all the 15 polymorphic loci. 
 
4.2.2	Electrophoresis	
 
Each PCR products is analysed, together with an allelic ladder, by capillary electrophoresis in order 
to identify the length of the amplified polymorphisms. 
Data are represented by an electropherogram (Fig 10) in which the presence of a specific 
polymorphism is revealed by a peak at a specific position on the x axis. The area under the peak is 
proportional to the abundance of the polymorphism. 
 
Fig.	10:	electropherogram	of	a	control	DNA	sample.	Each	green	bar	represent	a	microsatellite;	each	peak	correspond	to	the	
amplification	of	a	specific	polymorphism.	The	area	of	the	peak	corresponds	to	the	relative	amount	of	the	polymorphism.	
 
4.2.3	Data	analysis	
 
Each peak in the electropherogram has two main informations: the size of the polymorphism and 
the area under the curve. The size of each polymorphism is used to determine if the polymorphism 
belongs to the donor or the recipient, while the area under the curve is proportional to the relative 
amount of the associated polymorphism. 
 
4.3	Second	sample	collection	
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We then decided to apply this procedure to monitor dd-cfDNA dynamics from transplantation 
onward, to verify the possibility to use this analysis to monitor graft status and detect early rejection 
events, following the same procedure for plasma separation, cfDNA extraction and analysis 
described previously. 
	 51
RESULTS	
1	Validation	of	the	extraction	protocol	
	
Samples collected to validate the extraction procedure have been analysed as described in Matherial 
and Methods (2.3). Quantifications of the samples are summarized in Table 1 below. 
 
 MaxWell™ RSC (Promega) Abbott m2000 (Abbot) 
SAMPLE ng/µL ng tot ng/µL ng tot 
E.coli 0.5 MF 0.096 5.664 <0.010 - 
87173141 0.100 5.90 <0.010 - 
87180260 0.067 3.95 <0.010 - 
87182036 0.110 6.49 <0.010 - 
87187622 0.060 3.54 <0.010 - 
87189259 (1) 0.138 5.38 <0.010 - 
87189259 (2) 0.248 9.67 <0.010 - 
87191680 0.185 10.92 <0.010 - 
117002299 0.0156 0.9204 <0.010 - 
117002296 0.0132 0.7788 <0.010 - 
117002837 0.0139 0.8201 <0.010 - 
117003112 0.0160 0.944 <0.010 - 
117003115 0.0128 0.7552 <0.010 - 
117003410 0.0127 0.7493 <0.010 - 
 
Table 1: summary of quantification of cfDNA from samples coming from breast cancer affected patients used to validate the 
extraction procedure. 
	
2	Breast	cancer	
2.1	DNA	extraction	
	
DNA obtained from patients enrolled in the project was extracted and quantified as previously 
described, starting from 4 mL of plasma. 
Genomic DNA was extracted from 25 mg of fresh tissue and quantified as described in Materials 
and Methods (3.2). 
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Quantification of these samples are summarized in Table 2 below. 
	
	 cfDNA	 Fresh	tissue	
SAMPLE	 ng/µL	 ng tot	 ng/µL	 ng tot	
1	 0,35	 8,75	 49,4	 7410	
2	 0,39	 9,75	 35,1	 5265	
3	 0,56	 14	 42	 6300	
4	 0,26	 6,50	 40	 6000	
5	 0,65	 17	 71,1	 10755	
6	 1,07	 20	 85,9	 12885	
7	 0,26	 1,3	 47,1	 7065	
8	 0,44	 2,2	 47	 7050	
9	 0,14	 3,5	 46	 6900	
10	 1,42	 35,5	 163,3	 24495	
11	 1,16	 29	 144,6	 21690	
12	 0,07	 1,75	 42,1	 2105	
13	 0,93	 23,25	 33,8	 5070	
14	 3,17	 79,25	 229	 34350	
15	 8,7	 174	 150,5	 22575	
16	 17,4	 348	 207,2	 31050	
17	 28,3	 566	 63,8	 9570	
	
	
2.2	Target	enrichment	analysis	
	
Three runs of target enrichment and sequencing were by now performed. 
The first one comprised four samples of genomic DNA of patients 1 (ID 278399), 2 (ID 278400), 3 
(ID 278401) and 4 (ID 278402); the second one cfDNA samples of patients 1 (ID 293372), 2 (ID 
293373), 3 (ID 293374), and 4 (ID 293375); and the third genomic and circulating DNA of patients 
5 (IDs 295272 and 295274, respectively) and 6 (IDs 295273 and 295275, respectively). 
Fig 11 summarizes data regarding the total number of reads, those mapping and those with 
problematic matching of the three runs. 
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Fig. 11: total, mapped and problematic read of the samples of the three runs.  
 
Quality of the sequencing was determined as mean phred quality score, distribution of raw reads 
quality and raw reads length. An example of data obtained is described in Fig. 12. 
 
Fig. 12: example of reads quality evaluation in genomic DNA of patient 1. A) Along Cycle Quality 
measure the phred score, i.e. an evaluation of the correct base call, along the dimension of the fragment. 
A phred score value of 30 corresponds to a 99,9% accuracy of the base called during the sequencing. B) 
Distribution of the raw reads length: the peak at the end of the scale indicates that most reads have a high 
length, i.e. are of good quality. C) Mapping quality distribution: the location of the peak indicates the 
quality of the mapping. Optimally, most of the mappings are of high quality with a peak around 40, 
generally the higher the peak the higher the quality is. 
 
Soft-clipping is a value associated to incomplete matching between the full length read and the 
reference genome. This data is essential to understand if a read can be considered in the analysis or 
must be discarded. In this protocol, percentage of no soft clip above 75% can be considered reliable 
(Fig. 13). 
 
A B C 
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Fig. 13: pie chart illustrating the proportion of no soft 
clipping and soft clipping reads in genomic DNA of patient 1. 
As we can see in the box below the pie chart, >96% of the 
reads are no soft clipping, thus can be considered reliable. 
 
 
 
 
Mapping statistics give information on where the sequences mapped on the reference genome. This 
data indicated the accuracy of the target enrichment capture. If the sum of “onTarget” and 
“flankTarget” overcome 80%, target enrichment has captured the correct fragments, otherwise 
fragments in not-of-interest regions have been captured and analysed during the process (Fig. 14). 
The duplicate fraction percentage indicates if reads analysed are the result of an unbalanced PCR 
amplification or they belong to different amplicons. In genomic DNA analysis, this value should be 
between 20% and 40% to consider the analysis reliable, while values <20% can be considered 
excellent (Fig. 15). 
 
 
Fig. 14: Mapping statistics of genomic and circulating DNA from samples 5 (IDs 295272 and 
295274, respectively) and 6 (IDs 295273 and 295275, respectively). As we can see, the sum of 
“onTarget” and “flankTarget” percentages is more than the 80% considered as a threshold for 
good capture results. 
 
 
Fig. 15: Analysis of the duplicate fraction of genomic (IDs 295272 and 295273) and circulating 
DNA (ID 295274 and 295275) from patients 5 and 6, respectively. Percentages observed in 
genomic DNA are below 20%, suggesting a low levels of PCR amplification unbalance. cfDNA 
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samples, instead, have an higher percentage of sequences amplified by PCR. Columns named 2, 3, 
4, 5, 6-10, 11-100 and >100 indicates total number of reads having an equivalent number of copies 
(2 means two copies, 3 three copies etc). 
 
2.3	Identification	of	mutation	
	
The Sophia DDM software analysis allows to identify among the sequences the presence of 
mutation/s and simultaneously to classify it on the base of their effect: 1 - benign, 2 - likely benign, 
3 - uncertain, 4 - pathogenetic and 5 - definitely pathogenetic. Those mutation that have not been 
described yet in the ClinVar database are classified on the base of their predicted role in: A - 
definitively pathogenetic, B - potentially pathogenetic, C - unknown significance. 
The analysis also allows to distinguish between sequences presenting a low coverage respect to the 
threshold (x1000), i.e. are located in the “onTarget” region but data can not be considered reliable, 
those retained, i.e. have an above threshold coverage and thus data can be analysed, and those 
called “low confidence” SNVs/INDELS, grouping modifications associated to intronic or 
untranslated (UTRs) regions predicted to be of unknown significance (class C). 
2.3.1	Patient	1	
	
The analysis of the genomic DNA highlighted only a pathogenic mutation in the RAD51B gene 
with a variant fraction (VF) of 5.2% and classified as definitely pathogenic. 
The mutation consists of an insertion of a 100 bp fragment between nucleotides 80 and 81 that 
causes the formation of a stop codon, resulting in the truncation of the protein at Cys27 
(c.80_81ins100 p.Cys27*) (box below). 
 
 
 
The analysis of the cfDNA, however, did not detect any mutation of interest. 
 
2.3.2	Patient	2	
	
The analysis of the genomic DNA in this patient highlighted two pathogenic mutations. The first 
one is an insertion of a T between nucleotide 390 and 391, resulting in a stop codon and a truncated 
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protein at Arg131 (c.390_391insT p.Arg131*). It has a VF of 7.2% and is classified as definitely 
pathogenic (5). 
The second one is a missense mutation (T>A) at nucleotide 526 of the TP53 gene, resulting in the 
substitution of a cysteine with a serine (aminoacid 176), with a VF of 2.5% and a classification of 4 
(box below). 
 
 
The analysis of the cfDNA detected the mutation in the TP53 genes described also in genomic 
DNA but, interestingly, with a VF of 4.8% (figure below). 
 
 
2.3.3	Patients	3,	4	and	5	
	
The analysis on both genomic and circulating DNA in these patients did not revealed the presence 
of somatic mutation in genes of the panel. 
 
2.3.4	Patient	6	
	
The analysis of the genomic DNA in this patient highlighted two pathogenic mutations. The first 
one involved the BRCA2 gene and consist in the formation of a splice acceptor site due to the 
substitution of two A with one T at nucleotide 7436 (c.7436-2A>T). Its VF is of 13.7% and is 
classified as 5. 
The second one is a likely pathogenic (4), splice donor site in the TP53 gene, involving a deletion 
of nucleotides from 372 to 375 and an insertion of 2 G (c.372_375+2delinsG). The observed VF of 
this mutation is 14.1% (box below). 
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As for patient 1, the analysis of the cfDNA does not detect any mutation. 
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3	Septic	risk	
3.1	Validation	of	the	analysis	
	
We have firstly performed the analysis on 5 samples, to verify feasibility of the study. 
Circulating DNA was extracted as previously described. 
We performed a shotgun sequencing on whole cfDNA on a Illumina MiSeq v3 platform, following 
these conditions: 1x150 bp, single reads and 5 million reads/sample. 
All the samples have high quality (phred score higher than 20, fig. 16) so sequencing results have 
been sent to CosmosID to perform a metagenomic analysis on bacterial sequences. 
 
 
Fig. 16: diagrams repreesentig the phred score correlated to bp position in the sequence. Quality drop observed in last 
bases is due to Illumina Chemistry during sequencing. A) Sample: 92014656. As we can see phred score indicates a 
good sequencing. B) Sample: B.A. CVP. As for the previous sample, phred score is enough high to consider sequences 
obtained reliable 
 
The metagenomic analysis revealed the presence of variable percentage of bacterial sequences in 
each sample (Tab. 2). Only sequences belonging to the Propionibacterium branch overcome the 
threshold required to consider the detection reliable (Fig. 17). 
 
 
Tab. 2: percentage of human reads in cfDNA samples analyzed. 
 
SAMPLE %	OF	HUMAN	SEQUENCES
92014656 17.21
U.AG.	CVP 40.67
B.A.	CVP 54.21
A.F.	CVP 10.02
91778569 19.74
A B 
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Fig. 17: metagenomic analysis of cfDNA. As shown by the ‘Above_Threshold’ data, most of sequences analyzed are 
not enough confident to be considered sure. This analysis also allows us to detect the presence of antibiotic resistance 
genes and virulens factors. Box on the left represents results of the analysis performed on sample 92014656. Box on the 
right represent results of the anaysis performed on B.A. CVP. 
 
This data can be explained by different conditions: bacterial circulating DNA is a fraction of total 
cfDNA, thus 5 million reads/samples may not be enough to detect with an high coverage and 
confidence bacterial sequences, resulting in below threshold results; the identification of a branch is 
less specific than bacterial strain, in this sense the metagenomic analysis sum sequences belonging 
to different Propionibacterium strains, resulting in a higher confidence. 
To overcome these problems, we decided to improve the sequencing step by performing at least 10-
20000 reads/sample. 
 
We thus collect six more samples of blood from as much patients. We sequenced samples with 
these conditions: 1x150 bp, single reads and 10000 reads/sample. In four cases, plasma presented 
faint signs of haemolysis. We decided to perform analysis on these samples to verify the sensitivity 
of our technique in a sub-optimal condition. 
 
Percentage of human reads in four slightly haemolysed samples was high, ranging from 94% to 
97.6%, revealing a huge genomic contamination. As expected, no bacterial sequences were detected 
in 3 out of 4 samples. In sample PL, only E.coli was detected, but the low amount of reads did not 
allow us to consider it as a confident value (Fig. 18). 
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Fig. 18: identification of Escherichia coli in sample PL. As we can see, less than 1000 reads covers bacterial sequences, 
thus we can not consider this call statistically significant. 
 
The analysis of the two other samples revealed the presence of three and two bacterial strains, 
respectively (Fig. 19). 
Emoculture from patient summarized in fig. A revealed the presence of Staphylococcus 
epidermidis, while Propionibacterium or Streptococcus colonies were not detected. 
The presence of sequences belonging to Burkholderia multivorans in patient B is particularly of 
interest. This bacterium has a culture time of 7-14 days, much more than the common 5 days of 
emocultures, thus limiting the possibility of detection by this procedure. 
 
 
Fig. 19: metagenomic analysis of two cfDNA samples. In green: data whose confidence is above threshold, i.e. the 
presence is sure. A) Patient A. B) Patient B. 
A 
B 
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4	Transplant	monitoring 
 
The analysis of the three samples showing clinical symptoms suggesting an occurring graft 
rejection and, for this reason, undergoing renal biopsy did not presented dd-cfDNA, suggesting that 
rejection was not occurring. These data were confirmed by biopsy analysis. 
Fourth sample was analysed at four times: day 0 corresponding to 20 minutes after surgery; day 1, 4 
and 8 are days after surgery.  
As we can see from the figure 20 below, at the time of surgery we can detect nearly the same 
amount of polymorphisms belonging to the donor (e.g. sz148 and sz161 in panel E, sz166 or sz188 
in panel F) and the recipier (e.g. sz153 and sz157 in panel E and sz172 and sz184 in panel F), while 
1 day after surgery the areas of peaks corresponding to donor polymorphisms are highly reduced 
(panels G and H). 
 
 
Fig. 20: electropherograms of polymorphisms belonging to recipier (panels A and B), donor (panels C and D), 
transplanted recipier at surgery (panels E and F) and 1 day after surgery (panels G and H). We can see in panels E and F 
the relative amount of polymorphisms detected, described by the ar value, with a nearly equal amount of donor and 
recipient polymorphisms just after surgery. Panels G and H showed reduced amount of donor derived cfDNA compared 
to recipient one. 
 
 
Table 3 below summarizes percentage of recipient or donor cfDNA detected at different timepoints. 
The sudden reduction of percentage of dd-cfDNA at day 1 indicates that reperfusion injury is 
solving and graft damage is reducing. The complete abolishment of detection of dd-cfDNA at day 4 
and 8 is an indicator of good transplant outcome. 
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I.D. TIME RESULTS 
4 
DONOR V.G. 
DAY 0 ≈ 53% DONOR 
DAY 1 ≈ 10% DONOR 
RECIPIENT T.G. 
DAY 4 100% RECIPIER 
DAY 8 100% RECIPIER 
 
Tab. 3: summary of detection of donor derived cfDNA in blood sample of recipient at day 0, 1, 4 and 8. 
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DISCUSSION	
1	Breast	cancer	
	
The analysis of genetic alterations in tumours is becoming a routine in clinical practice due to the 
possibility to predict response to targeted-therapies or as prognostic markers, affecting progression-
free survival (PFS) and overall survival (OS) of many cancers. 
Nowadays, the gold standard in somatic alteration assessment is represented by tumour biopsy. This 
approach, however, have some limitations. First of all, it is an invasive approach that carries a high 
complications rate (Overman et al, 2013; Raaijmakers, Kirkels and Roobol, 2002). Then, biopsies 
allow to analyse only a small fraction of the tumour lesion, with a high risk of considering just a 
snapshot of the highly heterogeneous cancer (Shah et al, 2009). It is often necessary to repeat 
sampling of the tumour tissue and this procedure, besides intrinsic risks described above, is often 
considered unethical or impossible in cases of irradiated tumours (Schwarzenbach, Hoon and 
Pantel, 2011). 
The discovery of DNA circulating in blood opened the way to a surrogate marker for tumour tissue 
biopsy, called ‘liquid biopsy’. Blood drawing is a minimally invasive procedure that can be 
repeated several times without causing deep complication for the patient, but at the same time can 
furnish information on early cancer detection (Church et al, 2014), analyse the evolution of genetic 
abnormalities and monitoring tumour dynamics (Dawson et al, 2013; Ollson et al, 2013). 
Limitations on clinical application of cfDNA analysis are mainly related to the necessary 
development of novel, highly sensitive assays able to detect very low frequency mutations in small 
amounts of material with high sensitivity and specificity, to the lack of homogeneity on pre-
analytical procedure between different studies and to procedure that validate cfDNA based assay in 
comparison with actual gold standard approaches. 
The first biomarker we can consider is the total amount of cfDNA. Several studies have pointed out 
that cancer-affected patients have higher levels of circulating DNA, compared with healthy 
subjects. In non-small cells lung cancer (NSCLC) patients median concentration is eight time 
higher compared to heavy smokers controls, achieving a 75% sensitivity and 86% specificity in 
detecting NSCLC (Sozzi et al, 2003). 
cfDNA integrity has been evaluated as a diagnostic marker in colorectal cancers (CRC), 
periampullary cancers and BC. 
These two marker proved not to be widely applicable due to the inability to clearly discriminate 
between malignant and non malignant diseases such as chronic inflammatory disorders, thus having 
a high risk of false positive detection (Bettegowda et al, 2014). 
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Genetic alterations can be highly specific biomarkers that allow discriminating between malignant 
and non-malignant conditions. Cancer-specific epigenetic modification, such as hypermethylation 
of regulatory genes, can be a powerful marker in different cancers. Promoter methylation of SEPT9 
can help detecting CRC at early stages and a commercial test is under approval by Food and Drug 
Administration (FDA). Somatic mutations in oncogenes can be used as biomarkers to identify, 
evaluate prognosis and therapy and monitor cancer development (Franczak et al, 2018). 
In this work we have compared the detection of mutations in 16 genes (ATM , BARD1 , BRCA1 , 
BRCA2 , BRIP1 , CDK12 , CHEK1 , CHEK2 , FANCL , PALB2 , PPP2R2A , RAD51B , 
RAD51C , RAD51D , RAD54L , TP53) involved in homologous recombination (HR) in genomic, 
obtained from fresh tissue, and circulating DNA, obtained from plasma, in 6 patients affected by 
BC. 
We firstly validated the procedure to extract cfDNA from plasma, testing four different kits, two 
automated and two manuals, with starting plasma volumes ranging between 300 µl and 4 ml. In a 
second project, we also tested the difference in terms of cfDNA quality between the commonly 
used K3EDTA and the Blood STASIS 21-ccfDNA tubes, that contains an additive that prevents 
cells from lysis and preserve cfDNA from degradation for up to 21 days at room temperature. 
We conclude that, in order to obtain good amount of high quality cfDNA, the best procedure is to 
collect blood in the Blood STASIS 21-ccfDNA tubes, considering that it is not always possible to 
separate plasma within 1 h from venepuncture. 
The extraction has to be performed starting from at least 3 ml of plasma, considering that the more 
plasma can be processed the more cfDNA can be collected and analysed, increasing dramatically 
the representativeness of the sample in particular in the presence of mutations with very low VF. 
We choose the QIAamp MinElute ccfDNA Midi Kit (Qiagen) because it allows us to scale the input 
plasma volume from 3 ml to 10 ml and it gives better yield in comparison with the other manual kit. 
We observe a great variability in the levels of cfDNA in different samples, according with the 
literature. 
We performed the target enrichment protocol following manufacturer instructions and all the 
samples passed the QC. 
No mutations have been detected in 3 out of 6 samples analysed, either in genomic or circulating 
DNA. 
In two genomic samples we observe the presence of mutations. Surprisingly, no mutations have 
been detected in cfDNA obtained from these two patients. One of the reason underlying this result 
is that, despite QC of the target enrichment protocol did not revealed problems during the protocol, 
starting cfDNA was not enough to detect mutations at that frequencies. To better verify this 
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hypothesis and avoid such an outcome, future experiments will be performed on a greater amount 
of starting material, in order to reduce the risk of analyse a sample that results unrepresentative of 
the circulating DNA pool. 
In the last patient, a mutation in TP53 is observed in both genomic and circulating DNA, while the 
second mutation identified is present only in the DNA extracted from the fresh tissue. This latter 
situation can be explained as the two mentioned above. 
Interestingly, the VF of the mutation in TP53 is higher in cfDNA compared to genomic DNA. This 
data can be explained by the fact that it is probable that the tissue analysed contained only a fraction 
of the clone harbouring this mutation, while cfDNA, reflecting the whole tumour heterogeneity, is 
characterized by a higher frequency of mutated sequences. 
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2	Septic	risk	
	
The analysis of our 11 patients allowed us to set up the workflow and to verify the feasibility of our 
project. 
With the first analysis we observed a significant detection of just a Propionibacterium branch in 
two out of five samples. If from one side this data is compatible with the low amount of reads per 
sample, on the other the presence of Propionibacterium can be due to sample contamination. It is 
well reported in the literature that Propionibacterium bacteria can colonize foreign-body (Braun et 
al, 2013), especially prosthesis and venous accesses, giving rise to severe infections (Brook and 
Frazier, 1991). By now there is no way to determine, based only on sequence type and amount, a 
threshold that distinguishes a pathogenic from a non-pathogenic bacterium (Peaper and Durant, 
2019). 
Second set of samples allows us to further confirm the necessity to perform high numbers of reads 
per sample, as observed in patients A and B where we detected three and two bacterial strain, 
respectively. Parallelly, the analysis of slightly haemolysed samples results in no statistical relevant 
information on bacterial DNA fragments, suggesting the necessity to have high quality plasma and 
the possibility to introduce quality control analysis of plasma haemolysis more sensitive than visual 
inspection. 
Data obtained for samples A and B are quite promising. In the first case we have the simultaneous 
detection of Staphylococcus in emoculture and metagenomic analysis, while this latter indicates the 
presence of Propionibacterium and Streptococcus too. 
Metagenomic analysis on patient B revealed the presence of Burkholderia multivorans, a slowly 
growing bacterium that is hardly identified in emoculture due to a 7-14 days growing time. This 
data is probably the most interesting: a culture independent microbiology approach (Peaper and 
Durant, 2019), i.e. the possibility to identify the presence of bacteria independently of emoculture 
growing time and of bacterial ability to grow in standard emoculture conditions, by analysing 
circulating bacterial DNA can revolutionise microbiology the way we have seen it till now. 
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3	Transplant	monitoring		
 
The application of cfDNA analysis on graft monitoring has been widely described in the literature 
as a promising tool to avoid invasive and risky biopsies. 
In our project we want to verify the possibility to apply a well-established kit, commonly used to 
genotype and evaluate compatibility between donor and recipient, to monitor graft status and to 
early detect rejection events. 
The application of the AmpFlSTR® Identifiler® Plus PCR Amplification kit to plasma samples 
allows us to identify the presence of donor derived polymorphisms in cfDNA collected just after 
and 1 day after surgery. Since 4 days after surgery we do not observe dd-cfDNA, suggesting a 
complete recovery from reperfusion damage. 
There is limited information in the literatures regarding dd-cfDNA dynamics during early days after 
transplant. Beck and colleagues observed a 90% graft-derived cfDNA just after liver 
transplantation, rapidly decreasing to >15% at day 10 (Beck et al, 2013). Shen and colleagues 
observed a 20,69% dd-cfDNA levels after transplant, that decrease to 5.22% on the first day and 
then remain stable (Shen and Zhou et al, 2018). 
Our data are in accordance with the literature in observing a decreasing level of dd-cfDNA in the 
first days post surgery but a huge amount of data must be collected to perform statistical analysis. 
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FUTURE	PERSPECTIVES	
1	Breast	cancer	
	
One limitation of this study is the reduced amount of samples analysed. We are proceeding 
collecting samples of patients matching our inclusion criteria in order to increase the amount of data 
and this way have a better understanding of sensitivity and specificity of this method. 
Patients analysed will be monitored with further blood collection in order to verify the eventual 
occurrence of new mutations and data obtained will be crossed with the clinical status and 
development of the disease. 
Analysis of DNA extracted from peripheral white blood cells (WBC) can give us a deeper 
understanding of the somatic and germline mutational landscape in our patients, allowing us to 
better assign the role of mutations observed during the analysis. 
The further identification of mutations clearly associated with approved therapies (PARPi and 
platinum salts) can direct the clinical management of the patient toward a more efficient and 
specific treatment of cancer. 
 
2	Septic	risk	
 
We will increase sample collected and analysed, in order to verify the accuracy of our technique. 
The collection of control samples, possibly from healthcare professionals that are in contact with 
patients analysed, will allow us to determine if the detection of some bacteria can be ascribed to 
environmental/procedural contamination or it is reasonable to consider it as an infection. 
The possibility to have long-term emocultures will help us in verifying sensitivity of our technique 
in detecting low growing bacteria such as Burkholderia. 
Further increase in read per sample will be considered in order to increase information obtained by 
the metagenomic analysis, in particular regarding the presence of viral factors and, even more, 
genes conferring resistance to antibiotics, to better direct therapeutic approaches. 
 
3	Transplant	monitoring 
 
Our preliminary data suggest the possibility to effectively monitor graft status with this technique, 
as evidenced by data obtained on the fourth patient. 
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To further strengthen these data we are collecting more samples with time points described but also 
at several months after surgery or until the occurrence of clinical markers suggesting a rejection 
event. 
The correlation with clinical data will allow us to better understand the appropriateness of our 
conclusion based on cfDNA data. 
Finally, the availability of samples to retrospectively analyse patient having a rejection event will be 
extremely important to validate the sensitivity of our procedure in detecting early rejection events, 
thus considering it as a real monitor tool that can furnish information earlier compared with 
standard clinical procedures. 
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